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 Over the course of evolution, Nature has crafted innumerous enzymatic machines, 
capable of great feats of chemistry, across nearly all walks of life. These biocatalysts can 
construct incredibly complex molecular scaffolds, as demonstrated by the abundance of 
intricate natural products isolated from producing organisms. These compounds and the 
molecular machinery responsible for building them have inspired synthetic chemists for 
decades, but it is only more recently that technology has advanced to the point where the 
use of enzymes for organic synthesis has become feasible. Not only do biocatalysts often 
offer advantages over their small molecule counterparts in terms of ease of use, more 
mild conditions, greater selectivity, and faster reaction times, but also in the sense that 
many have evolved to operate synergistically with one another. This inherent coaction 
opens the possibility of performing enzymatic and/or chemoenzymatic cascades to 
construct complicated molecules in a one-pot fashion, chaining together multiple 
transformations and potentially streamlining chemical syntheses. Chapter 1 summarizes 
the history of biocatalysis in the context of organic synthesis, the current state of this field, 
and future prospects for this methodology in the synthesis of complex molecules.  
 The remainder of this thesis describes the use of enzymes from several 
biosynthetic pathways to construct members of an underexplored class of fungal natural 
products called azaphilones. This large family of compounds contains hundreds of 
scaffolds with unique structural features that impart a wide array of biological properties. 
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Though azaphilones represent a potentially untapped pharmacophore, their construction 
has proven challenging through conventional chemical syntheses.  
 In Chapter 2, I describe our rationale behind the motivation for using biocatalysis 
to construct azaphilones, the initial challenges associated with this goal, and our search 
for enzymatic catalysts to mediate the necessary dearomatization reaction towards 
constructing the azaphilone core. Using a sequence similarity network (SSN), we 
identified several previously uncharacterized flavin-dependent monooxygenase (FDMO) 
enzymes capable of mediating the desired reaction in a model system. Further analysis 
of these FDMOs also provided evidence for structural features of these enzymes that 
control the facial selectivity of the dearomatization reaction. 
 Having identified and characterized useful FDMO enzymes, we then constructed 
several azaphilone natural products through chemoenzymatic syntheses in Chapter 3. 
Two FDMO homologs, AzaH and AfoD, provided access to both enantiomers of an 
azaphilone bicycle, upon which the natural products trichoflectin and lunatoic acid A were 
built. Obtaining both enantiomers of trichoflectin through this methodology provided 
evidence for the structural revision of this compound, uncovering an error in the 
azaphilone literature on the absolute configuration assignment of these compounds. 
AzaH also provided access to another natural product, deflectin-1a, allowing for its 
structural revision, as well. 
 Finally, in Chapter 4, I describe the development of a dual-enzyme platform to 
construct azaphilone tricycle analogs. Several acyltransferases were identified using an 
SSN in an attempt to identify one suitable for the needs of this project. Ultimately, the 
acyltransferase (AT) MrPigD (PigD) was investigated for its ability to acylate the C7 
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hydroxyl group of azaphilone bicycles. Our studies indicate that this enzyme operates 
synergistically with AzaH in a one-pot sequential reaction, providing acylated azaphilones 
directly from five different orcinaldehyde precursors. This sequence platform also 
provided access to the natural product, rubropunctatin, through an unexpected cyclization 
of the acylated intermediate to afford a linear tricycle. Following analysis of the compound 
by UPLC, quantities of the natural product sufficient for NMR studies were obtained 
through a preparative scale biocatalytic reaction. This method was also applied to the 
synthesis of two other tricycle analogs, whose 1H NMR spectra suggest they are also 
linear tricycles. 
 The work presented in this thesis demonstrates the utility of leveraging FDMO and 
AT enzymes to construct complex azaphilones with greater ease and selectivity than 
achieved through conventional chemical syntheses. We anticipate that these methods 
will provide access to diverse libraries of molecules in a manner that is orthogonal to high-




Chapter 1: Introduction 
 
With excerpts from “State-of-the-art Biocatalysis”. Pyser, J. B.; Chakrabarty, S.; Romero, 
E. O.; Narayan, A. R. H. ACS Cent. Sci. 2021, Manuscript accepted.  
 
Summary 
 Enzymes have been used by humanity since our inception, and as our 
understanding of these macromolecular machines develops, they will continue to grow in 
their value to organic chemists. In addition, with the growing need to develop green 
alternatives in synthetic chemistry, biocataylsis represents a promising avenue to achieve 
this goal without sacrificing the activity and selectivity of conventional small-molecule 
catalysts. From its humble beginnings affecting simple manipulations like kinetic 
resolutions or reductive aminations in an academic setting, biocatalysis has now started 
to expand to the broader chemistry community. The internet and globalization have made 
it simple for anyone to obtain the tools and knowledge needed to use enzymes, greatly 
expanding the interest in and study of this field. State of the art techniques in 
chemoenzymatic synthesis and enzymatic cascades have now been applied in industrial 
processes to perform transformations with impressive yields and efficiency en route to 
highly valued drug scaffolds. As the technology continues to evolve, biocatalysis will 
provide new opportunities in high-throughput drug synthesis and screening, as well help 
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to streamline complex molecule syntheses, reinforcing the need to support the growth of 
these next-generation methodologies.   
 
1.1 Background 
The utility of naturally-occurring enzymes has been harnessed for thousands of 
years through fermentation and food preservation processes.1 Fascination with the 
chemistry of microbes originated at the dawn of the Neolithic era, nearly 12,000 years 
ago, when humans began domesticating grains and consuming alcohol, the evidence of 
which can be found in archaeological records.2 In fact, arguments have been made that 
our use of alcohol produced enzymatically even predates archaeological records, with 
evidence for ethanol-degrading enzymes present in primate species that lived before 
Homo sapiens.2 Driven by curiosity, people sought to understand how and why leaving 
cereals or grapes3 alone for some time caused them to adopt new properties, seeding 
fields like enzymology, molecular biology, and biocatalysis as an extension of this 
fascination.4 
Within the past few decades, biocatalysis in fine chemical and pharmaceutical 
production has surged.5-7 This trend is driven in part by advances in DNA sequencing, 
bioinformatics and protein engineering that allow for the identification of enzymes that 
Figure 1.1. A. Early uses of enzyme-mediated transformations, such as fermentation, chiral resolutions, and functional 
group interconversions. B. Recent advances in genome sequencing, gene synthesis, and bioinformatics increase the 
accessibility of obtaining enzymes. C. Select strategies in modern biocatalysis include cascades, chemoenzymatic 
synthesis, and enzyme evolution. 
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meet the reactivity and selectivity needs of a given synthetic route.8 Biocatalytic reactions 
are now routinely used in scalable processes ranging from simple chemical manipulations 
such as chiral resolutions,9-11 reductive aminations,9, 12 and alcohol oxidations,13 to 
complex, multistep chemoenzymatic cascades that enable access to high-value drug 
molecules on an industrial scale.14 The rapid developments in biocatalysis are also 
enabling a re-emergence of natural products in the current era of genomics.15 Natural 
products have a long history in drug discovery and development given their often potent 
biological activity. Still, the structural complexity of these compounds challenges chemists 
and demands a substantial time and resource investment to synthesize these compounds 
and analogs thereof.16 It seems undeniable that the next logical step in synthetic 
chemistry is to leverage the machinery that Nature has developed to access a similar 
breadth of complexity exhibited by these compounds.  
Biocatalytic methods also offer several key advantages over traditional chemical 
processes. These advantages include increased safety and sustainability, procedural 
simplicity, and the tunability of an enzyme's reactivity or selectivity through protein 
engineering.7 In particular, the sustainability profile of enzymatic transformations has 
motivated their adoption.17 In contrast to the organometallic catalysts developed using 
precious metals, which are being rapidly depleted from the Earth's crust,18 enzymatic 
catalysts can be produced without the worry of exhausting limited resources. These 
advantages poise biocatalysis for adoption into the mainstream synthetic repertoire.19 It 
is easier now than ever before for anyone, from enzyme novices to global biotech 
companies, to tap into the powerful transformations biocatalysis can offer. 
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In Chapter 1, we explore the diverse field of biocatalysis and highlight recent 
advances in technology that have dramatically improved the accessibility of enzymes and 
driven the transition from simple biocatalytic systems to sophisticated complexity-
generating biocatalytic platforms. Additionally, we highlight the advantages that 
biocatalysts offer in organic synthesis, the current state-of-the-art in this field, and how 
advancing technologies will provide new opportunities for incorporating biocataytic 
strategies in the synthesis of target molecules. 
 
1.2 Early Applications of Biocatalysis in Synthesis 
Despite their use in the fermentation process for millennia, enzymatic methods 
were first appreciated on the molecular level beginning in the early 1800s20 when 
researchers began investigating yeast for their fermentation abilities.21 Though it was first 
believed that the entire microorganism itself was functioning as the catalyst, the discovery 
of the first enzyme mixture, called "diastase", fundamentally changed the field by 
demonstrating that observed reactions were mediated by only  specific parts of the 
organism.22 This sparked increased interest in the then-new field of enzymology, and 
crucial milestones in understanding 
enzymes followed. These include 
the development of the lock and key 
model,23 cell-free fermentation,24 the 
realization that enzymes were in fact 
proteins,25 and the elucidation of the 
DNA structure,26 all of which have 
Figure 1.2. A. Dynamic kinetic resolution of racemic N-
acylhemiaminals by a lipase. B. NAD(P)H recycling system 
developed by Wong and Whitesides. C. Cascade system for 
construction of chiral amines using an ω-transaminase.  
Abbreviations: G6PDH – glucose-6-phosphate dehydrogenase, 




paved the way for modern biocatalysis.21 Finally, with the invention and adoption of X-ray 
crystallography, researchers were finally able to view the three-dimensional structure of 
these miraculous macromolecules in detail and gain insight into their functions and 
mechanisms.27 A more detailed account of the rich history of enzymology has been 
reviewed previously.21  
Over much of the 20th century and into the early 2000’s, the use of enzymes to 
perform useful chemistry truly gained popularity.21 Enzyme-mediated kinetic resolutions 
were one of the most common initial uses of biocatalysis in synthesis. Though several 
different classes of enzymes have been applied to conduct these enantiomeric 
enrichments,9 lipases are commonly employed to affect this transformation based on their 
commercial availability, large substrate scope, high levels of selectivity, and cofactor-free 
catalysis.11  Also commonly used in the production of cheese products and laundry 
detergents,28  the first member of this enzyme class was discovered in 1848 by Claude 
Bernard in his investigation of pancreatic secretions.29 Initial experimentation with lipases 
in the 1930’s30 and 1940’s31 laid the groundwork for their use in kinetic resolutions and 
other biocatalytic transformations for the rest of the 1900’s.11, 28 A relatively recent 
example published by Kaga and co-workers in 2003 demonstrates the simplicity of using 
lipases in a more modern biocatalytic setting; to construct a small library of chiral 
hemiaminals through the dynamic kinetic resolution of racemic starting materials.10 The 
group first screened a set of commercially available lipase enzymes for acylation activity 
against their library of racemic N-acylhemiaminals and determined that lipase QL gave 
short reaction times and operated with high levels of enantioselectivity. With this enzyme, 
they constructed several O-acylated hemiaminals in quantitative yields and in 
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high/exquisite enantioselectivities (Figure 1.2A). Lipase QL is just a select example 
among several others that demonstrates the early and widespread use of lipases and 
other kinetic resolution enzymes in academia and industry.28 
 The design of systems for in situ cofactor regeneration is a significant milestone in 
biocatalytic method development.32 Early studies of cofactor-dependent enzymes in 
synthesis relied on the addition of stoichiometric quantities of these cofactors, which 
limited the utility of the enzymatic reaction. Thus, the ability to continuously recycle these 
essential components in the reaction mixture was critical to certain biocatalysts' practical 
use.33 The early work of Wong and Whitesides on the regeneration of NAD(P)H in situ to 
enable reductions by dehydrogenase enzymes demonstrates this method’s capability and 
has since made an enormous impact on the field.34-36 To apply these dehydrogenases 
towards the construction of chiral alcohols, they developed the use of glucose-6-
phosphate dehydrogenase (G6PDH) from L. mesenteroides to reduce the NAD(P)+ 
cofactor in situ following its oxidation by the dehydrogenase. G6PDH relies on glucose-
6-phosphate, which is inexpensive and easy to synthesize, to provide the equivalent of 
hydride needed to reduce NAD(P)+ to NAD(P)H (Figure 1.2B). With this recycling system 
in place, Wong and Whitesides completed the biocatalytic generation of optically pure D-
lactic acid, threo-Ds(+)-isocritic acid, and (S)-benzyl-α-d1 alcohol.34 This early example of 
a biocatalytic cascade has since enabled the use of many enzyme-catalyzed reductions 
and has paved the way for application on industrial scale.37  
Since this preliminary work, methods relying on electrochemistry, photochemistry, 
other hydride donor/acceptor systems have been developed. For example, readily 
available reagents like isopropanol have been used in cofactor regeneration systems, 
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providing an alternative to the more expensive and labor-intensive sugars used 
previously.32 A variety of more economical and industrially-feasible sacrificial functional 
group donors have also been applied to improve efficiency, scalability, and ease of use of 
cofactor regeneration.38, 39 Several reports describe the use of isopropyl amine as an 
amino donor for transamination reactions, providing a substitute for the cost prohibitive 
amino acids used conventionally.40, 41 There is also a focus on the construction and 
regeneration of synthetic, biomimetic cofactors, which holds promise for increasing the 
effectiveness of these systems further.42 
The rapid adoption of recycling system methods allowed for the broad application 
of biocatalytic reduction reactions.37 The use of transaminases for constructing chiral 
amines is a prime example, and their utility in synthesis has been showcased in the 
synthesis of drug molecules such as sitagliptin.43, 44 Transaminases offer many 
advantages over their chemical counterparts, including improved stereoselectivity, mild 
reaction conditions, and reducing the reliance on harmful solvents and transition 
metals.43, 45 A notable example of the application of ω-transaminases, a subgroup of 
transaminases that has drawn particular attention in the pharmaceutical industry,46 was 
developed by Koszelewski and co-workers. Ultimately relying on a system similar to that 
produced by Wong and Whitesides to power catalysis, the Koszelewski group constructed 
nine chiral amines with excellent enantiomeric excess through a reductive amination with 
the commercial ω-transaminase ATA-113.12 They also employed a second enzyme, L-α-
amino acid dehydrogenase (L-AADH), to further streamline this reaction by regenerating 
the amino acid alanine in situ, which is the amine source for the transamination reaction. 
L-AADH, enabled by the NAD(P)H recycling system, utilizes an equivalent of ammonium 
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as the ultimate nitrogen source to reduce pyruvate to the desired alanine (Figure 2C). 
Albeit a relatively simple transformation by today's standards, this early work serves as a 
quintessential example of synthetic utility of transaminases. 
The seminal work highlighted here, alongside other early examples of simple 
biocatalytic reactions such as isomerizations, redox manipulations, and ligations,47 
brought to light the power of enzymes as catalysts in synthesis. In the more modern 
history of biocatalysis, there has been a paradigm shift from using enzymes to construct 
relatively simple building blocks or provide chiral intermediates for traditional syntheses,48 
to relying on them for late-stage synthetic modifications,49 combining molecule fragments 
towards value-added compounds, and conducting multistep, biocatalytically-mediated 
total syntheses.14, 37 Additionally, the tools for investigating and leveraging biocatalysts for 
synthetic uses have reached a stage where they are widely accessible to the chemistry 
community: obtaining the knowledge and equipment needed for biocatalysis can be 
accomplished with just a few clicks. 
 
1.3 Accessibility of Biocatalysis to Synthetic Chemists   
Once relegated to the fields of biochemistry and molecular biology, recent 
advances in bioinformatics,50 DNA sequencing,51 protein engineering,52 and DNA 
synthesis have made it possible for virtually anyone to take advantage of enzymatic 
catalysts and tailor them to their own needs. The process of identifying, producing, 
isolating, and tuning the reactivity of biocatalysts for desired transformations is as 
accessible to synthetic chemists as obtaining and using small molecule catalysts. In 
particular, the recent exponential growth in annotated protein sequences available in 
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online databases has created an enormous catalog of potential enzymes to serve many 
synthetic needs. Two of the most popular databases, UnitProt53 and Genbank54, now 
house information on more than 420,000 individual species, representing over one billion 
total sequence records. Instead of taking to the field and collecting specimens by hand to 
examine their genes, these databases store a wealth of information on protein sequence 
and origin and are a valuable starting point for anyone looking to identify enzymes for a 
given synthetic purpose.55 
Combining the vast amount of data stored in these online libraries with 
bioinformatic tools allows one to begin making predictions about the function of 
uncharacterized or "hypothetical" proteins,56 and to search for previously identified 
proteins that may also demonstrate activity in a non-canonical transformation.57 For 
example, the basic local alignment search tool (BLAST) is one of the most popular and 
easy to use for this type of analysis.58, 59 Gaining popularity in the early 1990s and now 
available to use for free on the National Center for Biotechnology Information (NCBI) 
website59, this tool relies on algorithms to search available online databases for protein 
sequences that resemble a given input sequence. By feeding the BLAST search engine 
a known nucleotide or amino acid sequence, or a protein identifier such as an accession 
number, the tool can align all known protein sequences that share similarity with the input 
sequence and rank them in a list. As minute changes in the order or position of amino 
acid residues can drastically alter function between homologous proteins with highly 
similar sequences, this type of search can be advantageous when trying to identify 
enzymes with improved stability and activity, complementary substrate scopes, or 
proteins that can perform desired transformations with the alternative site- and/or 
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stereoselectivity to the one used to build the query.36, 60, 61 This tool also provides known 
information about each sequence, such as the originating organism and any 
characterized metabolic function of the protein within said organism. By displaying data 
on the degree of similarity between proteins based on how well their sequences align, a 
user can quickly identify any known proteins that may share functional characteristics with 
the input protein sequence.62  
Albeit a useful starting point, this list format provided by BLAST can become 
cumbersome when the search yields thousands of potentially related protein sequences. 
To obtain a more comprehensive view of entire protein families, some of which can 
contain hundreds of thousands of proteins,63 tools have been developed that provide 
greater context for viewing connections within these groups. Phylogenetic trees are 
commonly used to examine relationships between homologous proteins and study 
Figure 1.3. A. Conceptual phylogenetic tree depicting locations of calculated ancestral sequences. B. Conceptual SSN 




changes in protein families over their evolution.64 This bioinformatic analysis technique 
relies on the alignment of homologous protein sequences to construct a visual 
representation of the evolutionary history of the related sequences in a phylogenetic tree 
(Figure 3A).64 Building and visualizing these trees has also been simplified by programs 
like the Molecular Evolutionary Genetics Analysis (MEGA)65, 66 and Ensembl67 that 
provide straightforward user interfaces. Once various algorithms and search tools are 
applied to analyze all available data and establish the most likely configuration, the trees 
can be examined to draw conclusions about relatedness among protein families and test 
hypotheses about their evolutionary origins.68, 69 
For example, one intriguing use of phylogenetic analyses in the context of 
biocatalysis is the identification and reconstruction of ancestral protein sequences (Figure 
1.3A) that can offer benefits in stability and biocatalytic activity over their modern 
"offspring".70 This technique relies on software to compare related protein sequences that 
most likely evolved from a common ancestor to calculate or "infer" the exact sequence of 
that ancestral protein.71 The ability to now obtain any DNA sequence quickly and easily 
makes reconstructing ancestral proteins a potentially powerful tool in identifying novel 
enzymes with desirable functions. To this effect, Furukawa et al. have identified an 
ancestor of 3-isopropylmalate dehydrogenase (IPMDH), a key enzyme in the biosynthesis 
of leucine, which offers improvements in its stability and activity over extant IPMDH 
enzymes from present-day organisms through construction and analysis of a 
phylogenetic tree.72 Following inference and identification of two ancestral protein 
sequences, dubbed ancIPMDH-IQ and ancIPMDH-ML, the group successfully expressed 
each protein in E. coli and, after isolating the enzymes for further investigation, discovered 
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they provided increased thermal stability and improved catalytic activity at low 
temperatures compared to their modern homologs.72 This work demonstrates just one of 
many potential uses for ancestral protein reconstruction, as other reports describe how 
ancestral proteins might possess higher degrees of substrate promiscuity compared to 
their modern offspring, thus offering potentially valuable characteristics to organic 
chemists seeking diverse and novel bond-forming activity.73  
Despite their utility and newfound ease-of-use, phylogenetic trees can still prove 
overwhelming when examining extensive protein families or groups of sequences.74, 75 
Tools like sequence similarity networks (SSNs) have emerged to help overcome these 
challenges. SSNs have gained much attention since its introduction to the bioinformatics 
community in 2003.76 It provides a way to visualize family-wide relationships and patterns 
in large groups of protein sequences by ranking sequences in "clusters" based on their 
alignment scores.74-77 These networks comprise groups of "nodes,” representing a protein 
sequence or group of sequences. These nodes are then connected by lines called 
"edges", representing a threshold for sequence similarity that can be set by the user 
(Figure 1.3B). Changing this score controls which nodes group together, allowing for 
inferences to be made about protein structure and functions by examining and comparing 
the location of nodes within the clusters.77 These networks can be constructed and 
analyzed quickly and easily through a web-based tool called EFI-EST75 and the free-to-
download software Cytoscape.76 Helpful tutorials and videos on how to construct, use, 
and manipulate SSNs with these programs are also available for free online.75, 76 
These networks can be beneficial for chemists looking to identify new enzymes for 
catalysis from families with a limited number of previously characterized proteins. Lewis 
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and co-workers have recently applied SSNs to identify and profile novel flavin-dependent 
halogenase (FDH) enzymes.78 Using these networks to guide their search, the group 
elected 128 initial halogenase sequences to sample for useful halogenation activity. 
Following expression of the genes, they obtained 87 soluble proteins for preliminary 
activity screens with 12 initial substrates containing a mixture of phenols, indoles, and 
anilines. Overall, the group identified 39 previously uncharacterized halogenases that 
demonstrated unique bromination and/or chlorination activity against the substrate panel. 
After examining an additional 50 complex and bulky substrates, they discovered at least 
one member of their halogenase library that demonstrated activity with around 48% of the 
substrates tested. Ultimately, Lewis and co-workers examined and characterized the 
preference for these FDHs towards bromination and chlorination, their site-selectivity, and 
thermostability and could draw further conclusions about trends in their SSNs through this 
family-wide profiling.78 This cutting-edge application of SSNs demonstrates how free and 
straightforward internet-based software can be used to identify synthetically tractable 
biocatalysts without the need to perform more complex mutagenesis and directed 
evolution experiments. 
Our group has also demonstrated the applicability of SSNs to examine previously 
uncharacterized enzymes with useful chemical functions.36, 74 We sought to identify 
homologous flavin-dependent monooxygenase (FDMO) proteins to investigate the 
factors that control their site- and facial selectivity in an oxidative dearomatization reaction 
and to identify enzymes suitable to enable a stereodivergent chemoenzymatic natural 
product synthesis campaign.36  Analysis of an SSN comprised of over 45,000 sequences 
from the flavin adenine dinucleotide (FAD) binding domain protein family (pfam01494) 
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identified several FDMOs that are highly similar to those our group had investigated 
previously.35 Combining the experimental data gained from reactions of these enzymes 
in a model system with comparisons of their sequence information and location in the 
SSN allowed us to identify trends in the SSN that predict the site-selectivity of a putative 
FDMO based on which cluster it is located in. We envisioned this technique may also help 
predict the stereoselectivity of the dearomatization mediated by a given FDMO, but further 
studies suggest that this is much more finely controlled than what can be predicted by a 
precursory SSN. Additional studies suggested two key active site residues are crucial in 
controlling the stereochemical outcome of the dearomatization reaction known to these 
proteins.36, 60 Though this does highlight a potential drawback of using SSNs in this way, 
the tool did ultimately demonstrate its utility in identifying other catalytically active proteins 
with desired activity. Work is currently underway to further characterize these enzymes in 
hopes of expanding our library of biocatalysts. 
Before developing these tools for identifying and characterizing enzymes in silico, 
obtaining biocatalysts for chemical experimentation was a significant challenge. To 
investigate a wild-type or naturally occurring catalytic protein, a molecular biologist would 
first need to get the source DNA or RNA encoding the gene of interest from the native 
organism. Following isolation, it is necessary to amplify the DNA fragment through a 
polymerase chain reaction (PCR)79. These amplified fragments must then be digested 
with restriction enzymes and ligated into a circular piece of DNA called a plasmid that has 
also been prepared with the same enzymes to ensure the ends of these sequences are 
compatible.80 Inserting DNA into a vector such as this not only allows for the host 
organism to uptake the gene of interest but can also be used to impart properties like 
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antibiotic resistance to the transfected cells to allow for the selection of individual cells 
that have successfully incorporated the plasmid. Following digestion, the prepared DNA 
fragment and cut vector are then combined in the presence of a DNA ligase enzyme, 
which efficiently joins the compatible ends of the fragment and vector, resulting in the 
production of a so-called "recombinant plasmid".81 In the case of transforming E. coli, one 
of the most popular and easy-to-use host organisms for recombinant protein production, 
the recombinant plasmid is then added to competent bacterial cells (cells that are primed 
to uptake foreign DNA from their surroundings). The cells can then be grown on agar 
media possessing an antibiotic to prevent cells that do not contain the plasmid from 
growing. After allowing the cells to grow on the agar, a colony can be harvested and 
analyzed to ensure that it possesses the desired gene. Finally, after ensuring the gene is 
present and contains the correct sequence, the colony can be used to seed a larger 
culture to harvest usable amounts of the desired protein, as well as to produce more of 
the plasmid for additional studies or to transfect new cells with the desired gene without 
having to undergo the entire process from scratch (Figure 1.3C).81 
In contrast to these traditional cloning techniques, technological breakthroughs in 
modern gene synthesis provide a highly streamlined process for chemists seeking DNA 
sequences and plasmids. Instead of using isolated DNA from native organisms as a 
template to amplify, solid-phase oligonucleotide synthesis allows for the de novo 
construction of any nucleotide sequence found online from individual nucleotide bases.82 
Companies now offer customized DNA constructs for purchase on-demand: input your 
insert sequence of interest and choose the desired vector in their online interface, and 
the company will ship you a ready-to-use recombinant plasmid possessing your exact 
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gene, or even a sample of host organisms containing the plasmid, in a matter of weeks. 
The cost is dependent on the number of base pairs in the DNA sequence and the 
particular plasmid desired, but these DNA constructs can typically be purchased for under 
200 USD. Not only does this save time and effort in obtaining the recombinant vector, it 
also allows for nearly anyone to take advantage of this technology without the need for 
specialized equipment, reagents and knowledge required for traditional cloning. 
Inexpensive and straightforward methods, reagents, and equipment for transforming, 
growing, and isolating recombinant protein from cells containing a mail order plasmid also 
lower the barrier for individuals and labs looking to enter the field of biocatalysis.83, 84 
These tools and techniques described above barely scratch the surface of what is 
available for anyone interested in using and tuning biocatalysts for a particular synthetic 
application.75, 85, 86 Advances in the fields of directed evolution52 and computer-guided 
enzyme engineering87 promise to construct enzymes with ever-greater efficiency, 
selectivity, stability, and reusability than those known today. Leveraging combinations of 
these strategies have already begun to provide highly applicable and useful biocatalysts 
to the synthetic community at large and will continue to improve biocatalytic methods as 
they are developed further.  
 
1.4 State of the Art Biocataklysis 
Following this explosion of interest in enzyme-mediated catalysis, biocatalytic 
reactions are now increasingly employed in complex molecule synthesis. Biocatalytic 
methods that affect late-stage site- and stereoselective C–H functionalization constitute 
one of the best state-of-the-art transformations available today that maximize step 
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efficiency and enable diversification of complex scaffolds. Select examples of biocatalytic 
C–H functionalization in complex molecule synthesis are shown in Figure 1.4A.  Sherman 
and co-workers have carried out a late-stage hydroxylation of the macrolide natural 
product M-4365 G1 (1.9) to form antibiotic juvenimicin B1 (1.10) with P450 
monooxygenase TylI.88 Late-stage biocatalytic C–H hydroxylation has also been explored 
in the pursuit of steroid-based drugs.89, 90 Zhou and co-workers developed a biocatalytic 
C19 hydroxylation of cortexolone (1.11) to form 19-hydroxycortexolone (1.12) using 
TcP450-1, a cytochrome P450 enzyme.90 This strategy enables direct access to bioactive 
C19-hydroxylated steroids.90 It is worth mentioning that direct hydroxylation at the C19 
position of steroids is extremely challenging using traditional chemical methods.91-93 Our 
research group's long-standing interest in using enzymes to carry out C–H hydroxylation 
reactions has been channeled for the late-stage diversification of paralytic shellfish 
toxins.94-97 We have employed the Rieske oxygenase SxtT to carry out the site- and 
stereoselective hydroxylation of β-saxitoxinol (1.13), directly generating saxitoxin (1.14).95 
The Renata group recently disclosed a non-heme iron (NHI) dependent enzymatic 
platform to enable late-stage biocatalytic hydroxylation of complex terpene scaffolds.98 
Figure 1.4. Biocatalysis in complex molecule synthesis: A) Selected C-H functionalization reactions. B) Selected C-
C bond forming reactions. 
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The enzyme P450BM3 MERO1 M177A was employed in carrying out selective C–H 
hydroxylation to form the oxidized terpene product 1.15.98 Direct C–H hydroxylation has 
also been developed for amino acid scaffolds. For example, Zaparucha discovered the 
NHI enzyme KDO1-3 that carried out selective hydroxylation of L-lysine.99, 100 The 
enzymes KDO1 and KDO2/3 selectively hydroxylated the C3 and C4 positions of L-lysine, 
and the enzyme KDO3 carried out C4 hydroxylation of a pre-C3-hydroxylated L-lysine.99 
Renata and co-workers employed the KDO1 mediated C3-selective hydroxylation of L-
lysine in their total synthesis of tambromycin.101  
Rapid advances in biocatalysis have resulted in the identification of enzymes that 
can carry out carbon-carbon (C–C) bond-forming reactions (select examples in Figure 
1.4B).102 Balskus and co-workers reported the enzyme CylK that carries out biocatalytic 
intermolecular Friedel-Crafts alkylation of two halogenated resorcinol derivatives to 
construct the cylindrocyclophane 1.19.103 The enzyme CylK has also been shown to be 
highly promiscuous, carrying out alkylation of a variety of resorcinol derivatives with 
secondary alkyl halides.104 Biocatalytic Friedel-Crafts alkylation has also been carried out 
to synthesize podophyllotoxin lignans.105, 106 For example, the NHI enzyme 2-ODD-PH 
has been utilized to carry out the biocatalytic synthesis of deoxypodophyllotoxin (1.20) 
and related analogs.106-108 Biocatalytic oxidative phenolic coupling reactions are emerging 
as powerful tools to construct complex molecules.109-111 The Müller group recently 
reported fungal P450 enzymes capable of carrying out oxidative coupling of coumarin 
derivatives in a site- and stereoselective manner.109 For example, the enzyme KtnC 
catalyzes the synthesis of the bicoumarin P-orlandin (1.21).109 Biocatalytic C–C bond 
formation has been explored in carbene transfers to generate chiral cyclopropanes.112-114 
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Arnold and co-workers first reported an engineered P450BM3 that carried out carbene 
transfer reactions. Diazoacetate reagents were used as the carbene sources to carry out 
alkene cyclopropanation.112 Several other groups have contributed to the development of 
biocatalytic carbene transfer reactions, and these have been applied towards the 
synthesis of pharmacologically relevant compounds such as the TRPV1 inhibitor 1.25.115, 
116 Biocatalytic carbene transfer reactions can be extended to alkynes as well, where the 
first carbene transfer generates a cyclopropene product which is primed for a second 
carbene transfer reaction to generate stereopure bicyclobutane products.117 This 
transformation rivals the best of what synthetic chemistry has to offer in terms of building 
complexity through C–C bond formation.  
In the case of selective C–H functionalization and C–C bond-forming reactions, 
biocatalysis is often employed at an advanced stage or in the final step of a synthetic 
campaign. Alternatively, biocatalysis can be engaged at an early stage in 
chemoenzymatic synthesis planning (Figure 1.5). In such cases, the product of a 
biocatalytic reaction is transformed into a target molecule of interest using modern 
synthetic organic chemistry tools. This strategic merge of biocatalysis and small 
molecule-based synthetic methods enables access to chemical scaffolds previously 
Figure 1.5. Chemoenzymatic sequences to complex molecules. A. Amino-acid C-H hydroxylation in the synthesis of 
manzacidin C. B. Hydroxylative dearomatization in the synthesis of azaphilone natural products. C. Benzylic 





unattainable using traditional chemical methods alone. For example, Renata and co-
workers developed a chemoenzymatic total synthesis of the natural product manzacidin 
C (1.32).118, 119 The NHI-dependent enzyme GriE was employed to carry out selective 
hydroxylation of an L-leucine derivative 1.30 to form 1.31.118 The product 1.31 was taken 
through established synthetic steps to formally assemble manzacidin C (1.32).118 Our 
group has been interested in the hydroxylative dearomatization of resorcinol compounds 
using flavin-dependent monooxygenases (FDMOs).35, 36 We have employed the site- and 
stereoselectivity of FDMOs in conjunction with small-molecule-based methods to enable 
the total synthesis of azaphilone natural products.36 For example, the enzyme AzaH was 
used to carry out the dearomatization of resorcinol 1.33 to form 1.34. The quinol product 
1.34 was subsequently transformed to (S)-trichoflectin (1.35) using chemical methods.36 
Our group has also focused on developing benzylic hydroxylation of o-cresol compounds 
using NHI-dependent monooxygenases.120 For example, we have employed the enzyme 
ClaD to carry out benzylic hydroxylation of resorcinol derivative 1.36, the product of which 
(1.37) undergoes spontaneous loss of water resulting in a biocatalytically generated o-
quinone methide, which was trapped using a chiral dienophile to construct the bioactive 
natural product xyloketal D (1.38).120 α-Deuterated amino acids are important building 
blocks towards the synthesis of labelled pharmaceuticals and biological probes, however, 
traditional methods to access these compounds often require protecting group 
manipulations121 and can be difficult to perform in a stereoselective manner.122 We 
discovered that SxtA AONS, α-oxoamine synthase evolved for saxitoxin biosynthesis, is 
capable of deuterating a range of unprotected amino acids and their methyl esters using 
D2O as the deuteron source. For example, deuteration of alanine methyl ester (39) 
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resulted in 1.40, which was subsequently transformed using chemical methods to access 
the deuterium-labeled Parkinson's pharmaceutical safinamide (1.41). 
Multi-enzyme cascade reactions have been developed in industrial and academic 
laboratories to enable complex molecule synthesis (select examples in Figure 1.5). The 
process toward HIV treatment drug islatravir (1.48) developed by Merck and Codexis is 
a representative example of a multi-enzyme cascade employed on an industrial scale.14 
The artificial nucleoside islatravir (1.48) was constructed using a combination of five 
enzymes from the nucleoside salvage pathway in bacteria, which were each engineered 
for a distinct purpose.14 This protecting group-free cascade yielded the product islatravir 
in markedly higher yields than previous chemical syntheses .14, 123 Moore and co-workers 
developed a multi-enzyme synthesis of complex halogenated bacterial meroterpenoids 
napyradiomycins A1 and B1 (1.54 and 1.55) in a single pot.124 Starting with three organic 
substrates (tetrahydroxynaphthalene 1.49, dimethylallylpyrophosphate, and geranyl 
Figure 1.6. Multi-enzyme biocatalytic sequences: A. Merck's biocatalytic synthesis of islatravir. B. Multi-enzyme synthesis 
of napyradiomycin A1 and B1. C. Multi-enzyme sequence towards the synthesis of tropolone stipitatic aldehyde. 
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pyrophosphate), the team developed a catalytic sequence involving five enzymes: two 
aromatic prenyltransferases (NapT8 and T9) and three vanadium dependent 
haloperoxidase (VHPO) homologs (NapH1, H3, and H4) to assemble the complex 
halogenated metabolites in milligram quantities.124 Our group has leveraged the exquisite 
reactivity of FDMOs and NHI-dependent monooxygenases to construct tropolone natural 
products.35, 125 Tropolones are a structurally diverse class of bioactive molecules that are 
characterized by a cycloheptatriene core bearing an α-hydroxyketone functional group. 
We developed a two-step, biocatalytic cascade to the tropolone natural product stipitatic 
aldehyde starting with the resorcinol 1.56. Hydroxylative dearomatization of 1.56 using 
TropB affords the quinol intermediate 1.57. The quinol intermediate undergoes oxidation 
by an α-KG dependent NHI enzyme TropC to form a radical intermediate which 
undergoes a net ring rearrangement to form stipitatic aldehyde 1.59. 
Biocatalytic methods are poised to significantly expanded the repertoire of 
transformations possible in an organic chemist's toolbox, allowing greater access to 
chemical space than previously possible. This creates an incentive for academic and 
industrial labs to embrace biocatalytic methods. As interest in this field continues to grow, 
it will most certainly inform the retrosynthetic logic of modern organic synthesis and shape 
the next generation of methods. 
 
1.5 Outlook and Conclusion 
New technology and approaches in biocatalysis continue to pave the way for 
innovation and paint a bright future this field. Enzymatic catalysis has demonstrated utility 
in the construction of simple molecules and holds promise for expanding synthetic access 
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to new corners of chemical space. The rapid technological advances surrounding 
biocatalyst discovery, characterization and application naturally raises the question as to 
what comes next in the field. We anticipate that the amenability of biocatalysis to high-
throughput experimentation will shape the application of enzymatic catalysis in synthesis. 
For example, we envision generation of compound libraries in plates will be possible 
through biocatalysis. Considering the benign nature of biocatalytic reactions, we 
anticipate biocatalytically generated compound libraries can be directly coupled with 
biological assays as well, matching the pace of compound generation with established 
high-throughput biological assays to ultimately accelerate drug discovery.126, 127  
Continued progress in biocatalysis would benefit combinatorial platforms for the 
synthesis of small-molecule-based compound libraries. The idea of combinatorial 
biocatalysis platforms for library synthesis has been around since the early 2000s; 
however, its widespread adoption has been hindered by the lack of resources to identify 
and develop promiscuous catalytic enzymes.128, 129 Combinatorial biocatalytic syntheses 
are now taking shape with recent advances in contemporary organic chemistry, synthetic 
biology, and bioinformatics. In addition, studies of enzyme cocktails have shown that 
biocatalysts can operate synergistically to complement each other's substrate scopes, 
creating useful catalyst mixtures to perform sequential chemical transformations.130, 131 
With this precedent, as well as equipment for high-throughput experimentation becoming 
more advanced and commonplace,126 it seems only a matter of time before the high-
throughput synthesis of vast and diverse small molecule libraries mediated by 
combinatorial biocatalysis is realized. 
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Without question, biocatalysis has become a valued approach in modern organic 
synthesis126 and is a methodology we will rely heavily on as the need to develop green 
alternatives in chemistry grows.17, 132 With the rapid advances in the field over the past 
few decades and the wealth of sequence data now widely available, biocatalytic methods 
are more accessible than ever before. As the global community adapts these techniques 
to their individual needs, new ideas and strategies will take hold and continue to push 
biocatalysis into the forefront of synthetic chemistry. 
 
1.6 Dissertation Outline 
 The following Chapters will focus on my research regarding the chemoenzymatic 
synthesis of azaphilone natural products and the development of the platforms utilized to 
achieve these syntheses.  
 Chapter 2, “Sequence Similarity Network Guided Characterization of Flavin-
Dependent Monooxygenases”, summarizes our studies on characterizing several 
known and unknown FDMOs identified through an SSN constructed for this protein family 
by Dr. Attabey Rodríguez Benítez (Figure 1.7A). To enable the stereodivergent synthesis 
of azaphilone natural products, it was necessary to identify FDMOs with complementary 
stereoselectivity to those examined previously by our group. Dr. Benítez first constructed 
this SSN using the sequences of FDMOs TropB, AzaH, and SorbC as input sequences. 
With assistance from Dr. Summer Baker Dockrey, seven previously uncharacterized 
FDMOs and one characterized one, AfoD, were selected for further investigation to 
examine trends between the location of these sequences in the SSN and their site- and 
stereoselectivity in a model dearomatization reaction. Our findings support a link between 
25 
 
which cluster a sequence is located in the SSN and its site-selectivity in the 
dearomatization reaction, indicating this tool can be useful in identifying biocatalysts with 
a desired site-selectivity in this reaction. However, these investigations have shown that 
the stereoselectivity afforded by these enzymes is more finely controlled than can be 
predicted by the SSN: evidence suggests that two active site residues play a major role 
in the facial selectivity of the dearomzation.  
 Chapter 3, “Chemoenzymatic, Stereodivergent Synthesis of Azaphilone 
Natural Product” discusses our efforts to synthesize azaphilone natural products with 
opposing C7 configuration using complementary biocatalysts (Figure 1.7B). Once Dr. 
Baker Dockrey, Dr. Rodríguez Benítez, and I determined FDMOs AzaH and AfoD would 
be suitable catalysts for this project, we constructed a focused substrate library to identify 
Figure 1.7. Visual overview of Chapters 2-4. A) Chapter 2, Sequence Similarity Network Guided Characterization of 
Flavin-Dependent Monooxygenases. B) Chapter 3, Stereodivergent, Chemoenzymatic Synthesis of Azaphilone Natural 
Products. C) Chapter 4, One-pot synthesis of tricyclic azaphilones using a dual-enzyme sequence 
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a suitable starting compound with functional handles for downstream chemistry. After we 
selected an orcinaldehyde bearing an enone group as the common intermediate, AzaH 
and AfoD were used to dearomatize this compound, ultimately providing access to both 
enantiomers of the natural product trichoflectin. Further characterization of these 
materials by Dr. Leo Joyce, Dr. Ren Wiscons, and myself provided evidence for the 
reassignment of the C7 configuration of the natural product from S to R, prompting me to 
investigate a related tricyclic azaphilone. Through comparisons to CD calculations 
provided by Dr. Joyce, my total synthesis of the natural product deflectin-1a allowed for 
structural revision of the deflectin series based on our findings, as well. Finally, I 
synthesized lunatoic acid A from the dearomatized intermediate accessed through AzaH, 
completing our stereodivergent syntheses.  
 I then pursued the synthesis of the other tricyclic azaphilone natural products  and 
analogs thereof in Chapter 4, “One-pot synthesis of azaphilone tricycles through 
sequential-addition biocatalysis” with the help of Dr. Ye Wang. To begin the 
investigation of chemoenzymatic generation of azaphilone libraries in a well-plate format, 
I investigated two acyltransferase enzymes, PigD and CazE, for their ability to 
functionalize azaphilone bicycles. Experiments were first performed to examine the 
activity of these enzymes both in a stand-alone reaction and in a one-pot sequential set 
up with the FDMO, AzaH, performing an initial dearomatization reaction (Figure 1.7C). 
Though CazE did not demonstrate any activity, UPLC and LC-MS analysis of the crude 
extracts from reactions containing PigD confirmed the formation of the desired acylated 
material. Following reaction condition optimization and purification of PigD, a focused 
substrate library was screened against the developed one-pot conditions, revealing that 
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PigD exhibits promiscuity toward azaphilone substrates. In addition, initial spectroscopic 
data gathered by Dr. Wang and myself suggests that the acylated product intermediates 
in this screen undergo an unexpected cyclization, forming linear tricycles as opposed to 
the expected angular tricycles. We performed preparative scale reactions to provided 
access to the natural product, rubropunctatin, and two other linear tricycle analogs for 
NMR studies. 
 The last section, Chapter 5, “Conclusions and Future directions”, will provide 
a summary of the thesis work and a discussion of next steps and future experiments for 
the one-pot synthesis project. 
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Chapter 2: Sequence Similarity Network Guided Characterization of Flavin-
Dependent Monooxygenases 
 
Reprinted (adapted) with permission from “Stereodivergent, Chemoenzymatic Synthesis 
of Azaphilone Natural Products”. Pyser, J. B.; Baker Dockrey, S. A.; Benítez, A. R.; Joyce, 
L. A.; Wiscons, R. A.; Smith, J. L.; Narayan, A. R. H. J. Am. Chem. Soc. 2019, 141, 18551-
18559. Copyright © 2019, American Chemical Society. 
 
Summary 
 Selective access to a targeted stereoisomer is often critical in synthesis of 
biologically active molecules. Whereas small-molecule reagents and catalysts are 
routinely available as either enantiomer, mirror-image biocatalysts are not readily acces-
sible, creating a challenge in the application of biocatalysis in synthesis. This difficulty is 
highlighted when considering the synthesis of members of the class of natural products 
known as azaphilones, which posses a hydroxyl group bearing either configuration at C7. 
To demonstrate the utility of biocatalysts to construct either enantiomer of the azaphilone 
core selectively, we sought to identify homologous enzymes capable of performing the 
desired oxidative dearomatization chemistry with complementary selectivity on the same 
aromatic precursor. However, despite the abundance of sequence information available 
in online databases, identifying reactivity trends between previously uncharacterized 
enzymes poses a significant challenge. Herein, we report the use of a bioinformatic tool 
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called a sequence similarity network (SSN), constructed by Dr. Attabey Rodríguez 
Benítez, to identify FDMOs providing complimentary selectivity in their activity with a 
model substrate. The constructed SSN was successful in predicting the site selectivity of 
chosen FDMOs in their dearomatization reaction based on their cluster location and 
provided evidence suggesting that the stereoselectivity of these enzymes is more finely 
controlled than can be predicted by their SSN location.  
 
2.1 Introduction 
 Biocatalytic approaches can provide numerous advantages in synthesis. These 
include high levels of selectivity, mild reaction conditions, and opportunities for cascade  
reactions that enable the rapid construction of complex molecules.1 These attractive 
qualities have drawn the attention of the synthetic community, sparking growth in the 
application of biocatalysis in the synthesis of bioactive compounds.2-7 When a particular 
biological activity motivates the synthesis of a target molecule, the ability to access 
individual isomers of the final compound is critical.8 Traditional chemical strategies for 
selective synthesis can provide tools to arrive at a predicted selectivity outcome. For 
example, the desired enantiomer can be accessed by employing chiral ligands that can 
be obtained from commercial sources or synthesized as either enantiomer.9, 10 This 
strategy is not currently applicable to biocatalytic approaches, as methods for generation 
of mirror-image proteins are in the early stages of development.11, 12 Protein engineering 
is commonly employed to address this problem (Figure 2.1A); however, there is no unified 
approach for enabling access to diverse selectivity outcomes biocatalytically. Here, we 
seek to address this drawback by employing an alternative approach to identifying panels 
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of catalysts which deliver complementary selectivity outcomes in a synthetically valuable 
transformation. 
Previously, our group has demonstrated the utility of select biocatalysts for site- 
and stereoselective oxidative dearomatization of resorcinol compounds.13 The flavin-
dependent enzymes used in this study provide distinct advantages over small-molecule 
reagents and catalysts for asymmetric dearomatization, as these biocatalysts are 
perfectly site-selective and avoid overoxidation that leads to undesired byproducts.13-15 
However, the set of biocatalysts reported previously hydroxylate to afford products with 
only the R-configuration at C3 (see (R)-2.12, Figure 2.1B) limiting the potential 
Figure 2.1. A) Approaches to enabling biocatalytic stereodiversity. B) Biologically active azaphilone natural products feature 
both the R- and S-configuration at the C7 stereocenter.17,21,23 Biocatalytic oxidative dearomatization gives access to either 
enantiomer via AzaH or AfoD mediated oxidation.  
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applications of this method. To access the enantiomeric set of products, we considered 
two approaches: protein engineering to achieve a switch in stereoselectivity or use of a 
natural enzyme with complementary selectivity.  
Over the last decade, there has been exponential growth in the number of 
annotated protein sequences available, due in part to the continuing decrease in the price 
of sequencing.16 This sequencing revolution coupled with improved bioinformatic tools for 
predicting enzyme class and function provides an alternative to protein engineering 
campaigns, making it increasingly possible to identify a natural enzyme that can perform 
a given biocatalytic reaction with the desired selectivity (Figure 2.1A). Based on the 
number of natural products that could biosynthetically arise through enantioselective 
hydroxylative dearomatization, we anticipated it would be possible to identify enzymes 
capable of providing the complementary stereoisomer to the flavin-dependent 
monooxygenases TropB and AzaH employed in our previous study (Figure 2.1B).13 Once 
stereocomplementary  catalysts have been identified, we envision that this suite of 
biocatalysts will enable the stereodivergent, chemoenzymatic synthesis of high-value 
molecules. 
To showcase this strategy, we targeted the azaphilone family of natural products. 
These compounds are characterized by an oxygenated pyranoquinone bicyclic core 
bearing a single tetrasubstituted carbon (Figure 2.1B).17 Isolated from fungal sources, this 
large family of natural products is known to contain a diverse array of structural features 
that impart a wide range of biological properties including anticancer,18-20 antiviral,21 and 
anti-inflammatory activities.20, 22 For example, luteusin A (2.6) and rubrorotiorin (2.8) were 
found to inhibit the binding of the HIV surface glycoprotein gp120 to the human CD4 
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protein, making these natural products potential starting points for the development of 
therapeutic agents against the virus.21 In addition, monascin (2.7), a tricyclic azaphilone 
natural product, has been shown to down-regulate steatohepatitis in a mouse model, 
indicating that these secondary metabolites have potential as therapeutics for non-
alcoholic fatty liver disease.23 As illustrated in Figure 2.1B, azaphilone natural products 
can contain either the R- or S-configuration at the C7-position. Several cases of epimeric 
azaphilones are known, in which each C7-epimer is produced by a distinct fungal 
source.24, 25 The pharmaceutical potential of these molecules has been demonstrated 
through initial in vitro and cell-based assays of isolated natural products;26-28 however, to 
gain a more comprehensive understanding of the therapeutic potential of these 
molecules, the challenge of constructing the densely functionalized core and C7-
configuration for exploration of this stereocenter’s impact on biological activity must be 
addressed.24, 25, 29 
 
2.2 Constructing an SSN of the FDMO PFam 
To survey the selectivity of flavin-dependent monooxygenases related by 
sequence, Dr. Rodríguez Benítez first constructed a sequence similarity network (SSN) 
of flavin-dependent monooxygenases (Figure 2.2A).30-32 SSNs are visual representations 
of the relatedness of protein sequences, which cluster based on similarity thresholds. This 
approach can enable the rapid and logical investigation of proteins likely to demonstrate 
similar reactivity and/or selectivity, dramatically reducing the time and search space 
required during screening, considerations critical to improving the compatibility of 
biocatalytic approaches and traditional synthetic strategies. The protein family 
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(Pfam01494) of flavin-dependent monooxygenases includes over 45,000 enzymes, 
which are included in the full SSN (Supporting Information Figure 2.6). This data set was 
truncated by limiting the search to edges possessing an alignment score greater than 
110, which returned 1,211 sequences (Figure 2.2A). She noted that the enzymes we had 
previously investigated, AzaH, TropB, and SorbC, were each located in distinct groups or 
“clusters” within the network, and that a fourth tight clustering of sequences formed 
between the TropB and SorbC clusters containing an enzyme associated with 
asperfuranone biosynthesis, AfoD.33-35 Previous in vivo studies35 and bioinformatic 
analysis34 indicated that AfoD is responsible for oxidative dearomatization of an 
asperfuranone precursor with the same site-selectivity as TropB and AzaH;34 however, 
the absolute configuration of asperfuranone suggests that AfoD carries out this 
transformation with the opposite facial selectivity.33  We hypothesized that sequences with 
high similarity to tropB, azaH, afoD, and sorbC would encode for enzymes that possess 
the ability to carry out oxidative dearomatization reactions, and further questioned if 
trends in site- and stereoselectivity could be predicted on the basis of sequence.  
 
2.3 Characterizing the Selectivity of Unknown FDMOs 
To test this hypothesis, seven sequences were selected on the basis of proximity 
to either TropB, AzaH, AfoD, or SorbC in the SSN by Dr. Baker Dockrey, Dr. Rodríguez 
Benítez, and myself (labeled FDMO1−7 in Figure 2.2A). Synthetic genes corresponding 
to the four known enzymes and FDMO1−7 were transformed into E. coli BL21(DE3) cells. 
Under standard expression conditions, Dr. Rodríguez Benítez obtained nine proteins 
successfully, whereas FDMO1 and FDMO3 proved insoluble under these conditions 
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(Figure 2.2B). The reactivity of the nine soluble enzymes was evaluated by Dr. Baker 
Dockrey and I with two substrates, S1 and S14. Gratifyingly, all nine enzymes showed 
activity with one of the two model substrates, eight of which displayed sufficiently high 
activity for product isolation from preparative-scale reactions (Figure 2.2B). A single 
product was obtained from each biocatalytic reaction, and a strong trend in site-selectivity 
was clear from these data: FDMO7, the enzyme most similar to SorbC, afforded C5-
hydroxylated product (see 2.16), whereas the remaining enzymes more similar to TropB, 
AzaH, and AfoD delivered C3-hydroxylated products (see 2.15). However, the trend 
between location on the SSN (Figure 2.2A) and stereoselectivity was not apparent. Dr. 
Rodríguez Benítez demonstrated that increasing the alignment score from 110 to 150 
Figure 2.2. A) Sequence similarity network (SSN) of FAD-dependent monooxygenases (Pfam01494) using a sequence 
alignment score of 110, made by Dr. Attabey Rodríguez Benítez . B) Results of expression, activity with model substrate S1 or 
S3**, site- and stereoselectivity of enzymes chosen from the SSN in panel A. *FDMO4 demonstrated <10% conversion by UPLC 
with substrate S1. C) Selected clusters from a more stringent SSN generated with an alignment score of 150 and corresponding 
analysis of the multisequence alignment of each cluster. 
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produced an SSN provided greater insight into the relationships between sequences in 
this family (see Figure 2.7 for full SSN). Notably, previously clustered sequences 
associated with divergent selectivity, such as AfoD and FDMO5, now clearly separated 
into distinct clusters (see Figure 2.2C). Analysis of sequence alignments between each 
of these clusters revealed conserved residues at positions 118 and 237 (AfoD 
numbering). In general, catalysts that generate products with the R-configuration possess 
a tyrosine at position 237 and an aromatic residue such as phenyalanine or tryptophan at 
position 118. In contrast, these conserved residues switch positions in biocatalysts that 
afford products with the S-configuration. Dr. Rodríguez Benítez previously demonstrated 
that a two-point coordination of the phenolate substrate by Tyr237 and an arginine residue 
is critical for positioning the substrate within the active site in the R-selective enzyme, 
TropB.36, 37 To probe the role of Tyr118 in the stereoselectivity provided by AfoD, she 
generated the AfoD Y118F variant. This was reacted with resorcinol 2.S1 to afford 
dearomatized product in 53:47 (S:R) er (Figure 2.12). These data provide additional 
evidence for the importance of this tyrosine residue in controlling stereoselectivity in these 
biocatalytic reactions and support the consideration of this sequence feature in choosing 
biocatalysts for a specific synthetic application. Obtaining additional structure and function 
data on these proteins will aid in demystifying the elements that contribute to the precise 
stereocontrol exhibited by these catalysts. Beyond the importance of Tyr position in the 
active site, it is clear that other mechanisms for stereocontrol have evolved in this class 
of enzymes. For example, Dr. Baker Dockrey showed previously that catalysts AzaH and 
SorbC break from this Tyr control mechanism, and, in the case of SorbC, she has 
proposed an alternative mechanism for control of substrate position in the active site.38 
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Ultimately, this survey of sequence space surrounding known enzymes provides a 
greater understanding of the sequence features that can predict site- and stereoselectivity 
and has increased the number of biocatalysts vetted for this transformation. With catalysts 
capable of delivering enantiomeric products in hand, we chose to pursue an 
enantiodivergent synthetic strategy with AzaH and AfoD based on the robust expression 
and reactivity of these enzymes, in addition to the excellent stereoselectivity of each 
catalyst. Under reaction conditions to dearomatize model substrate 2.S1 using AzaH and 
AfoD, enantiomeric bicycles (R)- and (S)- 2.S2 were accessed in >99% ee and 98% ee, 
respectively (Figure 2.12). 
 
2.4 Conclusion 
 Given the abundance of biological activity reported for the azaphilone natural 
product class, we sought to develop a method for their selective synthesis using a 
biocatalytic approach mediated by FDMOs. To provide a means to predict the site- and 
stereoselectivity of FDMOs in a model dearomatization reaction, Dr. Rodríguez Benítez 
constructed an SSN of PFam01494. Nine sequences were ultimately chosen from this 
SSN for further characterization based on their cluster location. After successful 
expression, it was found that all nine catalysts demonstrated activity in a model oxidative 
dearomatization reaction, with eight of the enzymes producing sufficient product yields 
for further characterization. We identified a trend between cluster location and site-
selectivity of these biocatalysts, suggesting that this bioinformatic tools can be used to 
predict this trait in previously uncharacterized protein sequences. However, no clear trend 
between SSN location and stereoselectivity was determined, demonstrating that this trait 
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is more finely controlled. Examining the PFam01494 SSN with an increased threshold 
scor0065, alongside follow-up experiments with an AFoD variant, suggests a link between 
the identity of two key active site residues and the stereochemical outcome of the 
dearomatization reaction. These findings help to better understand this class of enzymes 
and enable their use in biocatalytic syntheses. 
 
2.5 Experimental 
I. Substrate Synthesis 
All reagents were used as received unless otherwise noted. Reactions were carried out 
under a nitrogen atmosphere using standard Schlenck techniques unless otherwise 
noted. Solvents were degassed and dried over aluminum columns on an MBraun solvent 
system (Innovative Technology, inc., Model PS-00-3). Reactions were monitored by thin 
layer chromatography using Millipore 60 F254 precoated silica TLC plates (0.25 mm) that 
were visualized using UV, p-anisaldehyde, CAM, DNP, or bromocresol stain. Flash 
column chromatography was performed using Machery-Nagel 60 μm (230-400 mesh) 
silica gel. All compounds purified by column chromatography were sufficiently pure for 
use in further experiments unless otherwise indicated. 1H and 13C NMR spectra were 
obtained in CDCl3 at rt (25 °C), unless otherwise noted, on Varian 400 MHz or Varian 600 
MHz spectrometers. Chemical shifts of 1H NMR spectra were recorded in parts per million 
(ppm) on the δ scale. High resolution electrospray mass spectra were obtained on an 





Prepared as previously reported by Baker Dockrey et al.13 
 
II. Plasmids and Proteins 
 
Plasmids: The plasmid encoding azaH (G3XMC2.1), in a modified pET28 vector to afford 
protein with both C- and N-terminal 6 x His-tags, was a generous gift from Professor Yi 
Tang at the University of California, Los Angeles.19 The plasmid encoding afoD was 
synthesized by GeneArt and cloned into a pET21a vector. The plasmids encoding for 
fdmo1-7 were synthesized by Twist Bioscience and cloned into a pET28a vector. 
 



















































































































































































































































































Protein overexpression and purification: Plasmids containing the genes of interest 
were transformed using standard heat-shock protocols into chemically competent E. coli 
into BL21(DE3) cells. Overexpression of AfoD was achieved in 500 mL 4% glycerol (v/v) 
Terrific Broth (TB) in 2.8 L flasks. 500 mL portions of media were inoculated with 5 mL 
overnight culture prepared from a single colony in Luria Broth (LB) and 100 g/mL 
ampicillin (Gold Biotechnology).  Cultures were grown at 37 C and 250 rpm until the 
optical density at 600 nm reached 0.8. The cultures were then cooled to 18 C for 1 h and 
protein expression was induced with 0.1 mM isopropyl--D-1-thiogalactopyranoside 
(IPTG, Gold Biotechnology).  Expression continued at 20 C overnight (approx. 18 h) at 
200 rpm.  The typical yield for one 500 mL culture was ~15 g cell pellet. Overexpression 
of AzaH followed the same protocol as described above, except 1 L cultures were grown 
in 2.8 L flasks and kanamycin was used at 50 g/mL (Gold Biotechnology) in place of 




General purification procedure: 25-30 g of cell pellet was resuspended in 100 mL of 
lysis buffer containing 50 mM Tris HCl pH 7.4, 300 mM NaCl, 10 mM imidazole, and 10% 
glycerol.  Protease inhibitors were added to lysis buffer of AzaH only and consisted of 1 
mM phenylmethane sulfonyl fluoride (v), 0.1 mg/mL benzamidine HCl, 0.5 mg/mL 
leupeptin, and 0.5 mg/mL pepstatin.  Approximatley 1 mg/mL lysozyme was added to 
resuspended cells that were then incubated on a rocker at 4 C for 30 min.  Cells were 
lysed by passing the total cell lysate through an Avestin pressure homogenizer at 15000 
psi.  The total lysate was centrifuged at 40,000 x g for 30 min and the supernatant was 
filtered through a 0.45 m filter.  The crude cell lysate was loaded onto a 5 mL HisTrap 
HP column (General Electric) on an ÄKTA Pure FPLC system (General Electric) at a flow 
rate of 2.5 mL/min. Buffer A = the lysis buffer listed above, and Buffer B = 50 mM Tris HCl 
pH 7.4, 300 mM NaCl, 10% glycerol, and 400 mM imidazole.  The column was washed 
with 25 mM imidazole (6.3% Buffer B) for 6 CV and eluted in a gradient to 100% Buffer B 
over 8 CV.  Fractions containing AfoD or AzaH were visibly yellow and pooled for 
desalting on a PD10 desalting column.  Average yields: 100 mg from 1 L AfoD, 20 mg 
from 1 L AzaH. Molecular weights including 6xHis-tags for each protein were estimated 
by the ProtParam tool on the Expasy server to be 49.0 kDa for AfoD and 47.6 kDa for 
AzaH. These molecular weights are consistent with the mass of proteins bands observed 
by SDS-PAGE analysis (Figure 2.3).  The purified proteins were aliquoted into 0.6 mL 















Determination of flavin incorporation and extinction coefficients: Samples of each 
protein were diluted to 10 µM in 1 mL using dialysis buffer for UV-vis analysis using a 
disposable poly(methyl 2-methylpropenoate) cuvette.  The absorbance spectrum for each 
protein was taken from 300 nm to 700 nm in 2 nm increments (blue traces in Figure 2.4).  
A 20 µL aliquot of fresh 10% sodium dodecyl sulfate (w/v) was added to each 1 mL 
solution and mixed.  Samples were incubated at room temperature for 10 min before 
reading the absorbance spectra again under the same conditions (red traces in Figure 
2.4).  The absorbance at 450 nm for the denatured enzymes and the extinction coefficient 
of free FAD (11300 M-1 cm-1) was used to calculate the concentration of FAD in each 
protein sample using Beer’s law.  The typical FAD incorporation was 82% for AzaH, 81% 
for AfoD. Extinction coefficients were calculated using the concentrations of free flavin 
obtained and the absorbance at 450 nm of the native enzymes. At 450 nm, the extinction 
coefficients of the proteins are 17490 M-1 cm-1 for AzaH, 6,870 M-1 cm-1 for AfoD.  
Figure 2.3. Purified AzaH and AfoD.  Approximately 
5 µL of 1.25 µM each protein was loaded onto an 
MiniPROTEAN TGX Precast 4-15% SDS-PAGE gel 
(Bio-Rad).  The gel was stained with Quick 
Coomassie stain (Anatrace) and visualized with the 
Azure Gel Imaging System. The relative apparent 


































Comparision of  Native and  Denatured AfoD
 
 
III. Generation of AfoD Y118F variant 
General Considerations  
E. coli cloning strains DH5α (Invitrogen) were used for DNA propagation. Phusion HF 
polymerase was purchased from New England BioLabs. All primers were purchased from 
Integrated DNA Technologies (IDT) ddH2O was sourced from a MilliQ Biocel water 
purification unit from Millipore. 
Site-directed mutagenesis 
Table 2.1. Primer Sequences 
Variant Plasmid ID Oligo sequence 
AfoD Y118F AfoD_Y118F_P1 GAAAAGAACATGGCATTTTGGGCATGTC 
 
The AfoD(Y118F) substitution was generated by site-directed mutagenesis on pET151-
afoD(WT). 25 µL PCR reaction mixture contained 5 µL of 5X Phusion HF buffer, 1 ng/µL 
WT parent plasmid, 0.5 µM of primer, 200 µM dNTPs, 0.5 U µL-1 Phusion HF. 















Comparison of Native and Denatured AzaH
SDS-treated
Native















Comparison of Native and Denatured T ropB
SDS-treated
Native















Comparison of Native and Denatured SorbC
Native
SDS-treated
Figure 2.4. Native enzyme absorbance spectra compared to denatured enzyme absorbance spectra exposing free FAD 
to solution.   
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Amplification was accomplished with the following PCR protocol: 95 °C for 0:30 s, (95 
°C 0:30 95 °C for 0:30 s (-0.5 °C/cycle), 72 °C 0:30/kb) for 12 cycles, (95 °C for 0:30 s, 
65 °C for 0:30 s, 72 °C 0:30/kb) for 20 cycles  with a final extension of 72 °C for 10:00 
min. This was followed by a 10 µL digestion containing 1 µL of NEB CutSmart buffer, 8 
µL of PCR mixture and 20 units of DpnI. The reaction was incubated at 37 °C for 3 h 
and transformed into chemically competent E. coli DH5α cells. 
 
Protein Expression and Purification 
Protein overexpression: AfoD(Y118F) plasmid was transformed into E. coli strain 
BL21(DE3). 500 mL of Terrific Broth (TB) containing 100 µg mL-1 ampicillin was 
inoculated with 5 mL overnight culture prepared from a single colony in Luria Broth (LB) 
and 100 µg mL-1 ampicillin. The culture was grown at 37 °C and 250 rpm for 4 h. The 
culture was then cooled to 20 °C for 1 h at 200 rpm, and protein expression was induced 
with 0.1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) and expressed at 20 °C for 18 
h at 200 rpm. After overnight expression, cultures were centrifuged at 13,881 x g for 30 
min. Cell pellets from overexpression were stored at -80 °C for long-term storage. 
 
General purification procedure: Cell pellets from overexpression were resuspended in 
40 mL of lysis buffer (50 mM Tris:HCl pH 7.8, 300 NaCl, 10 mM imidazole, and 10% (v/v) 
glycerol) with 0.1 mg mL-1 lysozyme, 0.05 mg mL-1 DNase, and 0.1 mM flavin adenine 
dinucleotide (FAD), incubated on a rocker at 4 °C for 45 min, and lysed by sonication. 
Insoluble material was removed by centrifugation (46,413 x g for 30 min). The cell pellet 
was resuspended in 40 mL lysis buffer (50 mM Tris:HCl pH 7.8, 300 NaCl, 10 mM 
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imidazole, 10% (v/v) glycerol) with 0.1 mg mL-1 lysozyme, 0.05 mg mL-1 DNase, and 0.1 
mM FAD, incubated on a rocker at 4 °C for 45 min, lysed by sonication and cleared by 
centrifugation (46,413 x g for 30 min). The supernatant was incubated with Ni-NTA on a 
rocker for 2 h at 4 °C, followed by purification by gravity using a 25-50 mM gradient with 
increments of 5 mM imidazole. Protein was eluted with 100% elution buffer (50 Mm 
Tris:HCl pH 7.8, 300 mM NaCl, 400 mM imidazole, 10% (v/v) glycerol). Concentrated 
protein was desalted over a PD-10 desalting column (GE Healthcare). The protein was 
concentrated further using a 30 kDa centrifugal concentrator at 4,000 x g, 4 °C. 
Concentrated protein was divided into 100 µL aliquots, frozen in liquid nitrogen and stored 
at -80 °C. 
 
Figure 2.5. AfoD(Y118F) SDS-PAGE gel. The gel was stained with Quick Coomassie stain (Anatrace) and visualized 




IV. Sequence Similarity Network (SSN)  
 
 
Figure 2.6. SSN of flavin-dependent monooxygenases (pfam 01494) created using web tools originating from the 












V. FDMO Sequence Alignment  
 
Figure 2.8. AfoD cluster sequence alignment with other sequences within its cluster Y118 and F237 are highlighted. 
Alignment is colored by conservation. 
 
 
Figure 2.9. FDMO5 cluster sequence alignment with other sequences within its cluster Y118 and F237 are 




Figure 2.10. TropB cluster sequence alignment with other sequences within its cluster Y118 and F237 are 

















VI. Biocatalytic Reactions  
 
Stock solutions: Stock solutions of each substrate (50 mM) were prepared by dissolving 
the substrate in DMSO (analytical grade). Stock solutions of NADP+ (100 mM) and 
glucose-6-phosphate (G6P, 500mM) were stored at -20 °C. Aliquots of each flavin-
dependent enzyme and glucose-6-phosphate dehydrogenase (G6PDH, 100 U/mL) were 
stored at -80 °C. Analytical-scale reactions: Each reaction contained 25 μL 100 mM 
potassium phosphate buffer, pH 8.0, 2.5 mM substrate (2.5 μL of a 50 mM stock solution 
in DMSO), 5-20 μM flavin-dependent monooxygenase, 5 mM G6P (0.5 μL, 500 mM), 1 
mM NADP+ (0.5 μL, 100 mM), 1 U/mL G6P-DH (0.5 μL, 100 U/mL), and Milli-Q water to 
a final volume of 50 μL. The reaction was carried out at 30 °C for 1 h and quenched by 
addition of 75 µL acetonitrile with 25 mM pentamethylbenzene as an internal standard. 
Precipitated biomolecules were pelleted by centrifugation (16,000 x g, 12 min). The 
supernatant was analyzed by UPLC-DAD and conversion obtained by comparison to 
calibration curves of each substrate. The subsequent liquid chromatography PDA 
spectrometry (UPLC) analysis was performed on a Waters Aquity H-Class UPLC-PDA 
using a Phenomenex Kinetex 1.7 µm C18, 2.1x150 mm column under the following 
conditions: Method A: mobile phase (A = deionized water + 0.1% formic acid, B = 
acetonitrile + 0.1% formic acid), 5% to 100% B over 1.5 min, 100% B for 1.0 min; flow 
rate, 0.5 mL/min; Method B: mobile phase (A = deionized water + 0.1% formic acid, B = 
acetonitrile + 0.1% formic acid), 5% to 100% B over 2 min, 100% B for 1 min; flow rate, 
0.5 mL/min. Based on calibration curves of the starting materials, the percent conversion 
of the substrate to dearomatized product was calculated with AUCsubstrate/AUCinternal 
standard at 270 nm. All reactions were performed and analyzed in triplicate.  
 
General procedure for in vitro preparative-scale reactions: Preparative–scale 
enzymatic reactions were conducted on 20 mg of each substrate under the following 
conditions: 5-20 µM flavin-dependent monooxygenase, 2.5 mM substrate, 1 mM NADP+, 
1 U/mL G6PDH, and 5 mM G6P for NADPH generation in reaction buffer (50 mM 
potassium phosphate buffer, pH 8.0). The reaction mixture was added to a 50 mL 
Erlenmeyer flask and incubated at 30 °C with 100 rpm shaking. After 2 h, a 50 µL aliquot 
was removed and processed in an identical manner to the analytical-scale reactions 
described above to determine substrate conversion. The remaining reaction mixture was 
diluted with acetone (2 x total reaction volume). Precipitated biomolecules were pelleted 
by centrifugation (4,000 x g, 12 min). Isolation procedure: The supernatant was 
concentrated under reduced pressure to a final volume of approximately 2 mL. The 
resulting mixture was filtered through a 0.22 µm filter and purified by preparative HPLC 
using a Phenomenex Kinetex 5 µm C18, 150 x 21.2 mm column under the following 
conditions: mobile phase A = deionized water + 0.1% formic acid and B = acetonitrile + 






VII. UPLC Traces of Biotransformations 
Figure 2.11. Oxidative dearomatization of 2.S1 by AfoD and AzaH. PDA traces of 





 Retention Time Area % Area Height 
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VIII. Determination of Enantiomeric Excess 
 
Figure 2.12. PDA traces of racemic 2.S2 obtained from an IBX-mediated oxidative 
dearomatization, (S)- 2.S2 obtained from AfoD-mediated oxidative dearomatization, (R)- 
2.S2 obtained from AzaH-mediated oxidative dearomatization, and 2.S2 obtained from 
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Peak No % Area Ret. Time  Cap Factor 
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5 iPrOH AD-H Chiral 
Analytical 
sbdIV-087-rac 40 3.5 30 120 
 
 
Peak No % Area Ret. Time  Cap Factor 
1 99.6447 3.14 min 0 
2 0.3553 4.31 min 0 
 








Figure 2.13. PDA traces of racemic 2.S4 obtained from an IBX-mediated oxidative 
dearomatization and (S)- 2.S4 obtained from FDMO7-mediated oxidative 






































Figure 2.14. PDA traces of racemic 2.S2 obtained from an IBX-mediated oxidative 
dearomatization, (R)- 2.S2 obtained from FDMO-2 and FDMO-5-mediated oxidative 
dearomatization, and (S)- 2.S2 obtained from FDMO-6-mediated oxidative 
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 Name Retention Time Area % Area Height 
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Chapter 3: Stereodivergent, Chemoenzymatic Synthesis of Azaphilone Natural 
Products 
 
Reprinted (adapted) with permission from “Stereodivergent, Chemoenzymatic Synthesis 
of Azaphilone Natural Products”. Pyser, J. B.; Baker Dockrey, S. A.; Benítez, A. R.; Joyce, 
L. A.; Wiscons, R. A.; Smith, J. L.; Narayan, A. R. H. J. Am. Chem. Soc. 2019, 141, 18551-
18559. Copyright © 2019, American Chemical Society. 
 
Summary: 
 Azaphilones represent a class of fungal natural products containing a highly 
oxygenated pyranoquinone bicyclic core and a tetrasubstituted carbon. While they often 
function as fungal pigments, many possess potent biological activity including anti-cancer, 
anti-microbial, and anti-inflammatory properties. Despite continued efforts towards their 
investigation, the biological activity of these compounds remains underexplored due to 
the synthetic challenges presented by their densely functionalized core and congested 
stereocenter. Having identified a number of biocatalysts that operate with complementary 
site- and stereoselectivity to access the azaphilone bicyclic core, the biocatalysts AzaH 
and AfoD were employed by Dr. Summer Bakery Dockrey and I towards the 
stereodivergent, chemoenzymatic synthesis of several azaphilone natural products. 
Specifically, the first syntheses of trichoflectin, deflectin-1a, and lunatoic acid A were 
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achieved. In addition, chemoenzymatic syntheses of these azaphilones supplied 
enantioenriched material for reassignment of the absolute configuration of trichoflectin 
and deflectin-1a based on optical rotation, CD spectra, and X-ray crystallography. These 
chemoenzymatic routes have simplified the stereoselective synthesis of azaphilones, 




 The ability to rapidly construct complex molecules with ease is a major hurtle in 
the identification and investigation of new biologically active compounds. Furthermore, 
with the increase in cases of antibiotic resistant infections and chemoresistant cancers, 
the need for highly selective and facile synthetic transformations is ever-growing.1 To 
diversify these compounds for identification of drug leads, so called “modular synthesis” 
presents a unique approach to accessing the necessary breathe of chemical space. This 
method seeks to break down complex chemical structures into basic, interchangeable 
building blocks or modules, allowing for straightforward diversification strategies using 
highly-selective catalysts. This modularity enables chemists to more easily construct 
libraries of related compounds, providing a means to pinpoint which changes in the 
peripheral chemical structure increase activity towards a particular biological target 
through structure-activity relationship (SAR) studies.1 However, although this approach 
promises insight into the details of minute changes to natural product scaffolds, the speed 
and precision with which current synthetic methods can be used to construct analogs is 
a significant bottleneck. 
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Benefitting from eons of evolution, the molecular machines responsible for 
generating natural product scaffolds are a logical starting point to begin the construction 
of more potent and selective drug candidates to combat current health crises. To 
overcome accessibility challenges in the context of azaphilone natural product synthesis, 
we sought to improve synthetic methodology towards these molecules using biocataylsis.  
Existing approaches for the construction of these molecules rely either on the cyclization 
of linear precursors2 or, more commonly, the oxidative dearomatization of highly 
substituted resorcinol intermediates.3-5 This biomimetic, dearomative strategy has proven 
valuable as it allows for the installation of structural complexity through well-established 
arene functionalization methods prior to the generation of the bicyclic core. Established 
approaches for oxidative dearomatization of azaphilone precursors have employed 
oxidants such as hypervalent iodide reagents5-7 or Pb(OAc)4.3 Racemic syntheses of 
azaphilones have been reported using these reagents; however, achieving high levels of 
enantioselectivity can be a challenge. Enantioenriched azaphilones have been accessed 
using Porco and coworkers’ copper-oxo (–)-sparteine dearomatization strategy,8 
achieving the total synthesis of (-)-mitorubrin with 97% ee,9 as well as that of (+)-
sclerotiorin and (+)-8-O-methylsclerotiorinamine from a common precursor obtained in 
98% ee.10 This method requires superstoichiometric quantities of both the oxidant and 
chiral ligand. To date, there has yet to be a report of a highly enantioselective, catalytic 
oxidative dearomatization using a small- molecule catalyst. Furthermore, the application 
of asymmetric oxidative dearomatization to the synthesis of tricyclic members of the 
azaphilone family, such as rubropunctatin and rubrotiorin, has yet to be reported. As such, 
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the absolute configuration of many of these 
natural products, which are typically assigned 
by analogy, has yet to be confirmed.6, 11  
 
3.2 Identifying a Common Intermediate 
Having demonstrated the ability to 
synthesize either enantiomer of azaphilone 2.S2 
in Chapter 2, we sought to complete the 
stereodivergent syntheses of two biologically 
active azaphilone natural products. To identify a 
common intermediate that would provide 
versatility in accessing an array of azaphilone 
natural products, Dr. Baker Dockrey and I synthesized a number of aromatic substrates 
were subjected them to oxidative dearomatization with stereo-complementary 
biocatalysts. We hypothesized that the orcinaldehyde motif and homobenzylic ketone 
group would be critical for substrate recognition. In addition, we desired a functional 
handle to enable late-stage functionalization of the eastern portion of the azaphilone 
scaffold. Interestingly, the AzaH native substrate was not converted by AfoD (Table 3.1, 
entry 1). We hypothesize that the β-hydroxy group prevents the substrate from engaging 
in productive binding interactions and leads to the lack of activity of AfoD as the native 
substrate of AfoD features a hydrophobic group at this position.12 This is supported by 
the activity of the saturated ketone substrate with AfoD (entry 2), which does not contain 
this polar functional group. 
Table 3.1. Substrates screened for conversion by 
AfoD (0.8 mol %) and AzaH (0.8 mol %). *NADPH 
recycling system: G6P (2 equiv), NADP(+) (0.4 




     Promisingly, two alkynyl substrates that are intermediates in the synthesis of 
the ketone substrates are accepted by AzaH (entries 3 and 4); however, neither alkyne 
substrate was converted by AfoD. The α-methoxy ketone substrate (entry 5) was initially 
pursued as a promising intermediate as the dicarbonyl was fully converted by AzaH, but 
gave low conversions with AfoD. A simple methyl ketone derivative (entry 6) 
demonstrated activity with both enzymes as well; however, its low activity with AfoD 
ultimately disqualified it as the common substrate. The enone substrate depicted in entry 
7 was efficiently dearomatized by both AfoD and AzaH in 83% and 95% conversion, 
respectively. The high conversions observed for this compound with both enzymes and 
the synthetic handle afforded by the double bond made it an ideal candidate for the 
common intermediate in our envisioned divergent synthesis of azaphilone natural 
products. 
Despite its suitability in this role, the established route to this compound at the time 
involved a lengthy and often challenging ten step synthetic sequence.8, 9 This route also 
relied on an expensive and volatile cross-coupling partner to install the alkene 
functionality at a late stage, which was undesirable. Therefore, to provide access to 
sufficient quantities of this enone substrate for further investigation, a new route was 
devised. Beginning from the commercially available and inexpensive reagent, methyl 
atratate, the phenolic groups on this compound were first MOM protected to yield 3.S4. 
Weinreb amide 3.S5 was then synthesized and appended to 3.S4 to provide Weinreb 
ketone 3.S6 bearing the desired enone moiety. In spite of attempts to optimize this 
transformation, we achieved a maximum isolated yield of 30% of the desired product. We 
attribute this low yield to starting material consumption by the competing 1,4-addition 
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reaction of 3.S4 with the Weinreb amide, as opposed to the desired 1,2-addition. 
However, given that this step occurs early in our synthesis and can be performed on large 
scale, we deemed this yield sufficient for our purposes. 
Having installed the enone functionality, we then set about reducing the ester 
present in the starting compound to the desired aldehyde. First, the newly installed 
carbonyl was protected from reduction through a base-mediated cyclization, generating 
lactone 3.S7. This lactone was then reduced to the corresponding lactol 3.S8. Next, we 
envisioned a global MOM deprotection under acidic conditions, anticipating that lactol 
3.S8 would also open to reveal the desired aldehyde and ketone of the final compound. 
No productive reaction was observed under conventional deprotection conditions, 
prompting us to investigate Lewis acids to mediate this transformation. We found that 
NbCl5 was able to cleanly deprotect both phenols while simultaneously opening the lactol, 
furnishing the desired enone 3.4. Rigorous purification of this material was required, as 
any remaining Lewis acid appeared to render the material inactive in the enzymatic 
transformation. Thus, a maximum isolated yield of 50% was achieved for this step. 
Ultimately, this synthesis provided streamlined access to 3.4, reducing the longest 
linear step count from a commercially available reagent to five steps from the previous 
ten (see Experimental for details on this synthesis). This sequence was subsequently 
used to provide material for our syntheses of azaphilone natural products. 
 
3.3 Synthesis of Trichoflectin 
Angular azaphilone, trichoflectin (3.1), was the first natural product target chosen 
as a model for route development that would enable the synthesis of more complex 
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tricyclic azaphilones. First isolated by Sterner in 1998, trichoflectin exhibits moderate 
antimicrobial activity as well as the ability to inhibit DHN-melanin biosynthesis in certain 
fungal species.13 Despite interest in the biological activity of this compound, no total 
synthesis of trichoflectin has been reported to date. Our proposed retrosynthesis is 
described in Figure 3A. We envisioned constructing the butenolide ring of trichoflectin 
through an intramolecular Knoevenagel condensation following acylation of bicycle 3.2.6, 
11 To obtain the reported (-)-trichoflectin, the C7-stereocenter would be set by 
stereoselective oxidative dearomatization of enone 3.4 with AzaH.  
The synthesis of trichoflectin was initiated through a five-step route to enone 3.4 








200 300 400 500
Figure 3.1. (A) Retrosynthetic analysis of the natural product trichoflectin (1). (B) Total synthesis of (S) and (R)-trichoflectin. 
(C) Calculated and measured CD data for (S) and (R)-trichoflectin. (D) Total synthesis of (S)-deflectin-1a (10). (E) Calculated 






scaffold (R)- 3.5 in 96% yield and >99% ee (Figure 3.3B). Next, acylation of (R)- 3.5 with 
the acylketene generated in situ from precursor 3.6 followed by Knoevenagel 
condensation provided (S)-trichoflectin ((S)- 3.1) in 99% yield. This level of selectivity was 
not expected as Franck and coworkers reported the isolation of both angular and linear 
tricycles when constructing the butenolide ring of a similar azaphilone scaffold, proposing 
the distribution of these products is controlled by the steric properties of the acyl group.11 
However, in our system, the desired angular tricycle was produced exclusively. We 
attribute this to a difference in electronic properties of the extended π-system and have 
observed through attempts to reduce the C8-ketone that this position is more electrophilic 
than the C6-ketone. 
Unexpectedly, the sign of the optical rotation of our synthetic (S)- 3.1 was opposite 
to that which is reported for the natural product (measured +34.1 CHCl3, reported -121 
CHCl3).13 To rule out the possibility of stereocenter inversion during the construction of 
the butenolide ring or that the enzyme performed the dearomatization on this particular 
substrate with unanticipated facial selectivity, a CD spectrum was calculated by Dr. Leo 
Joyce and compared to the measured spectrum of synthetic (S)- 3.1. As depicted in 
Figure 3.1C, the calculated CD spectrum for (R)-trichoflectin is equal and opposite to the 
measured spectrum from (S)-trichoflectin, initially suggesting that the C7-stereocenter 
had been installed as anticipated. Ultimately, an X-ray crystal structure was obtained of 
the AzaH-produced tricycle by Dr. Ren Wiscons, unambiguously confirming the C7-
configuration of (+)-trichoflectin as S (Figure 3.1B). Based on this data, we suspected that 
the natural product was misassigned. A 1976 report, which has been the basis for 
assignment of absolute configuration in the case of trichoflectin and many other 
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azaphilone natural products, suggests that the optical rotation of these compounds is 
controlled solely by the C7-stereocenter.14 However, we have found that the electronic 
properties of the azaphilone core, as well as the presence of other stereocenters in the 
compound, can have a significant impact on the optical rotation based on computational 
modeling (see Experimental). To confirm the configuration of the natural product as R 
rather than S as assigned upon isolation, the enantiomeric tricycle was synthesized from 
the AfoD generated product (S)-3.5 (Figure 3.1B). The optical rotation of (R)- 3.1 was 
measured as -47.4, agreeing in sign with the characterization of the isolated natural 
product. Therefore, it is proposed that the structure of the natural product be revised to 
the R-configuration. 
 
3.4 Synthesis of Deflectin-1a 
 This revision prompted a careful inspection of the absolute configuration of 
structurally related angular tricycles. An azaphilone series called the deflectins, which are 
reported to possess inhibitory activity of bacteria and erythrocytes as well as cytotoxicity 
towards carcinoma cells, share the same tricyclic core as trichoflectin (Figure 3.1D).15 
Upon isolation, the absolute C7-configuration was assigned solely by optical rotation, as 
was done in the case of 3.1.13 Comparison of the calculated CD spectrum produced by 
Dr. Joyce of deflectin-1a to that of trichoflectin showed a good correlation (see 
Experimental, Figures 3.13 and 3.19), indicating that these compounds should exhibit 
similar optical properties. The deflectins are reported to possess the R-configuration at 
C7 and a corresponding optical rotation in the positive direction. This assignment 
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disagrees with the data collected for the trichoflectin enantiomers. Thus, it was deemed 
likely that this series was also assigned incorrectly. 
     To answer the question surrounding the absolute configuration of these molecules, we 
sought to complete the total synthesis of (S)-deflectin-1a (3.10, Figure 3.1D). As this 
compound contains a methyl group in place of the 1,2-disubstituted double bond found in 
trichoflectin, methyl ketone 3.7 was dearomatized with AzaH to produce bicycle 3.8 in 
95% yield and >99% ee. Although AfoD also accepts 3.7 as a substrate (Table 3.1, entry 
6), AzaH was used due to higher turnover and isolated yield in this reaction. Acylation 
and subsequent Knoevenagel condensation with the acylketene derived from precursor 
3.9 furnished the desired butenolide to deliver (S)-deflectin-1a in 87% yield. The spectral 
data for 3.10 matched all available reported values. A measured optical rotation of +88.4 
for this S-enantiomer confirms the need for structural revision of the natural product from 
the R-configuration to the S at C7. 
 
3.5 Syntheisis of Lunatoic Acid A 
With both trichoflectin and deflectin-1a in hand, we set out to construct the natural 
product lunatoic acid A (3.11), which was reported to possess the opposite configuration 
at C7 to the newly established configuration of natural trichoflectin and deflectin-1a. 
Isolated by Marumo, this natural product exhibited interesting antibacterial properties, as 
well as the ability to act as an antifungal agent by inducing chlamydospore-like cells in 
certain fungi.16, 17 As depicted by the retrosynthesis in Figure 3.2A, we envisioned 
accessing the carboxylic acid moiety of 3.11 through a cross metathesis with the C9,10 
double bond of intermediate 3.12.9 We anticipated that the chiral aliphatic ester of 3.12 
83 
 
could be constructed through an acylation of the C7-hydroxyl group of (R)- 3.5, which 
would be accessed through dearomatization of common intermediate 3.4 with AzaH. 
Having established a robust method for biocatalytic dearomatization of enone 3.4, 
the first challenge we encountered en route to lunatoic acid A was the acylation of tertiary 
alcohol 5. While the acylation had proceeded smoothly with the ketene en route to 
trichoflectin and deflectin-1a, our attempts at acylation of 3.5 using acyl chlorides or 
symmetric anhydrides consistently failed to produce chiral ester 3.12, affording only 
starting material or under more forcing conditions, complete decomposition of 3.5. 
Ultimately, we discovered that Yamaguchi esterification with 3.13 (Figure 3.2B) did afford 
the desired product, although after optimization of reaction conditions, a maximum 50% 





190 265 340 415 490
Figure 3.2 A) Retrosynthetic analysis of azaphilone natural product lunatoic acid A (3.11). B) Total synthesis of lunatoic acid 
A (3.11). C) Calculated and measured CD data for lunatoic acid A methyl ester* (3.14). *NADPH recycling system: G6P (2 





carboxylic acid, prepared as previously reported.19 The carboxylic acid moiety present in 
lunatoic acid A was appended as the masked methyl ester through olefin metathesis with 
methyl acrylate and Grubbs 2nd generation catalyst in 48% yield.20 Our attempts to 
perform the metathesis prior to esterification resulted in decomposition of the starting 
material, indicating that protection of the C7-hydroxyl group increases the stability of the 
compound to the reaction conditions. The expected mass of lunatoic acid A was observed 
by TOF-MS upon saponification of methyl ester 3.14 using LiOH; however, sufficient 
quantities of the pure compound for NMR studies could not be obtained. This observed 
instability parallels the nature of the free acid from culture extracts. These extracts were 
methylated to obtain lunatoic acid A methyl ester (3.14), which was fully characterized in 
lieu of the free acid.16 All spectral data from the fully synthetic 3.14 match with reported 
literature values, including an agreement in the sign of the optical rotation and Cotton 
effects from the reported CD, indicating in this case that the original assignment of R at 
C7 is accurate.16 
 
3.6 Conclusion 
 A set of complementary biocatalysts for oxidative dearomatization have been 
identified and applied to the enantiodivergent, chemoenzymatic synthesis of azaphilone 
natural products. A focused substrate library was created to identify a suitable common 
intermediate for dearomatization by both AzaH and AfoD. These enzymes were then used 
to construct both enantiomers of scaffold 3.5 to access the desired natural products 
containing either the R-or S-configuration at C7.  The AzaH-produced scaffold (R)- 3.5 
was initially used to access the natural product trichoflectin ((S)- 3.1); however, it was 
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discovered that this tricycle contained the opposite stereocenter from the natural product 
based on its optical rotation, CD spectral data, and X-ray crystal structure. Synthesis of 
the opposite enantiomer of trichoflectin ((R)- 3.1) was achieved using the dearomatized 
scaffold accessed through AfoD, with an optical rotation that led to the reassignment of 
the C7-stereocenter of trichoflectin to S from the original literature report of R. This 
prompted the construction of related tricycle deflectin-1a (3.10) using analogous 
substrates, which allowed for the reassignment of its C7-stereocenter. Lunatoic acid A 
(3.11) was then constructed from (R)- 3.5 and its structure confirmed through CD spectra 
and optical rotation. We anticipate these methods will enable the rapid construction of 
libraries of natural and unnatural azaphilones. 
 
3.7 Experimental 
I. Substrate Synthesis 
All reagents were used as received unless otherwise noted. Reactions were carried out 
under a nitrogen atmosphere using standard Schlenck techniques unless otherwise 
noted. Solvents were degassed and dried over aluminum columns on an MBraun solvent 
system (Innovative Technology, inc., Model PS-00-3). Reactions were monitored by thin 
layer chromatography using Millipore 60 F254 precoated silica TLC plates (0.25 mm) that 
were visualized using UV, p-anisaldehyde, CAM, DNP, or bromocresol stain. Flash 
column chromatography was performed using Machery-Nagel 60 μm (230-400 mesh) 
silica gel. All compounds purified by column chromatography were sufficiently pure for 
use in further experiments unless otherwise indicated. 1H and 13C NMR spectra were 
obtained in CDCl3 at rt (25 °C), unless otherwise noted, on Varian 400 MHz or Varian 600 
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MHz spectrometers. Chemical shifts of 1H NMR spectra were recorded in parts per million 
(ppm) on the δ scale. High resolution electrospray mass spectra were obtained on an 
Agilent HPLC-TOF at the University of Michigan Life Sciences Institute. 
 
List of reagents prepared or purified: 
2-Iodoxybenzoic Acid (IBX) was synthesized according to the procedure described by 
Sputore et al.21  








Aryl bromide S1 (150 mg, 0.65 mmol), PdCl2(PPh3)2 (23 mg, 0.033 mmol, 0.050 equiv), 
CuI (12 mg, 0.065 mmol, 0.10 equiv) was stirred in 4.8 mL of anhydrous DMF in a flame-
dried round bottom flask equipped with a stir bar. Et3N (0.30 mL, 2.2 mmol, 3.3 equiv) 
was added and the mixture was sparged with N2 for 15 min before methyl propargyl ether 
(0.11 mL, 1.3 mmol, 2.0 equiv) was added. The resulting mixture was heated to 60 °C for 
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14 h. The reaction mixture was cooled to rt, diluted with water (2.0 mL), and acidified with 
1 M HCl (4.0 mL). The mixture was extracted with EtOAc (3 x 10 mL) and the combined 
organic layers were washed with water and brine, dried over anhydrous Na2SO4, filtered, 
and concentrated under reduced pressure to afford a dark brown solid. Purification on 
silica gel (10-20% EtOAc in hexanes) afforded 135 mg (94% yield) of S2 as a tan solid. 
1H NMR (400 MHz, CD3OD) δ 10.04 (s, 1H), 6.47 (s, 1H), 4.33 (s, 2H), 3.41 (s, 3H), 1.98 




To a mixture of 3.S2 (20 mg, 0.091 mmol, 1.0 equiv) and Au(OAc)3 (1.7 mg, 0.0046 mmol, 
0.050 equiv) in DCE (1.0 mL) was added TFA (0.091 mL, 1.2 mmoL, 13 equiv) in a flame-
dried vial under N2. The resulting mixture was stirred for 1 h at rt before 10 mL of 20% 
H2O/MeCN was added. The mixture was stirred for 12 h at rt before it was diluted with 
water (1.0 mL) and extracted with EtOAc (3 x 5.0 mL). The combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated under reduced pressure to 
afford a dark brown solid. Purification on silica gel (80% EtOAc in hexanes) afforded 20 
mg (92% yield) of 3.S3 as a light tan solid. 1H NMR (400 MHz, CD3OD) δ 9.82 (s, 1H), 
6.23 (s, 1H), f.02 (s, 2H), 3.39 (s, 3H), 2.00 (s, 3H);13C NMR (150 MHz, CD3OD) δ 205.8, 
193.4, 163.7, 163.0, 137.0, 112.3, 110.2, 110.1, 76.4, 58.1, 41.0, 5.9; HR-ESI-MS: m/z 
calculated for C12H15O5 [M+H]+: 239.2465, found: 239.2465; IR (thin film): 2921, 2827, 












Methyl 2,4-bis(methoxymethoxy)-3,6-dimethylbenzoate (3.S4) 
Methyl atratate (13 g, 66 mmol, 1.0 equiv) in THF (650 mL) was cooled to 0 °C and NaH 
(60%, 7.9 g, 200 mmol, 3.0 equiv) was added portionwise. MOMCl23 (15 mL, 200 mmol, 
3.0 equiv) was slowly added to the resulting mixture. The solution was warmed to rt and 
stirred for 5 h before it was cooled to 0 °C and quenched with NH4Cl (500 mL, saturated 
aq.). The layers were separated, and the aqueous layer was extracted with EtOAc (3 x 
500 mL). The combined organic layers were washed with NaHCO3, dried over Na2SO4 
and concentrated under reduced pressure to afford a yellow oil. Purification on silica gel 
(0-20% EtOAc in hexanes) afforded 15 g of the ester as a colorless oil (90% yield). 1H 
NMR (300 MHz, CDCl3): δ 6.72 (s, 1H), 5.19 (s, 2H), 4.96 (s, 2H), 3.89 (s, 3H), 3.54 (s, 





Crotonic acid (10 g, 120 mmol, 1.0 equiv) was dissolved in oxalyl chloride (12 mL, 140 
mmol, 1.2 equiv) and stirred at 70 °C for 1 h. The resulting acyl chloride was distilled at 
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124 °C, then added to a solution of N,O-dimethylhydroxylamine hydrochloride (10 g, 100 
mmol, 0.90 equiv) in DCM (190 mL). The mixture was cooled to 0 °C before pyridine (21 
mL, 260 mmol, 2.2 equiv) was added slowly. The mixture was stirred at 0 °C for 30 min, 
then allowed to warm to rt for 30 min before it was diluted with 1 M HCl (150 mL) and 
extracted Et2O (3 x 150 mL). The combined organic layers were washed with brine (300 
mL), dried over MgSO4, and concentrated to afford a red oil. Purification on silica gel (60-
80% Et2O in hexanes) afforded 12 g (82% yield) of the title compound as a pale yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 6.98 (m, 1H), 6.41 (d, J = 15.4 Hz, 1H), 3.69 (s, 3H), 






Diisopropylamine (9.1 mL, 65 mmol, 1.1 equiv) in THF (300 mL) was stirred at -78 °C. n-
BuLi (2.5 M in hexane, 26 mL, 65 mmol, 1.1 equiv) was slowly added. The resulting 
mixture was warmed to 0 °C and stirred for 15 min before it was cooled to -78 °C and a 
solution of ester 3.S4 (15 g, 20 mmol, 1.0 equiv) in THF (50 mL) was added. The resulting 
mixture was stirred at -78 °C for 15 min before a solution cooled to -78 °C of amide 3.S5 
(9.2 g, 71 mmol, 1.2 equiv) in THF (25 mL) was added by cannula. The mixture was 
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stirred for 1 h at -78 °C and was then acidified with 1 M HCl (aq. 100 mL). The layers 
were separated, and the aqueous layer was extracted with EtOAc (3 x 400 mL). The 
combined organic layers were washed with brine (400 mL), dried over Na2SO4, and 
concentrated under reduced pressure to afford a yellow oil. Purification on silica gel (5-
15% EtOAc in hexanes) afforded 4.5 g of an inseparable mixture of the title compound 





NaH (170 mg, 4.50 mmol, 1.05 equiv, 60%, dispersion in mineral oil) was stirred in THF 
(290 mL) at -20 °C.  Enone 3.S6 (1.5 g, 4.3 mmol, 1.0 equiv) in THF (50 mL) was slowly 
added to the suspension. t-BuOH (10 μL) was added and the solution was stirred for 1 h 
at 20 °C. The reaction was cooled to 0 °C and quenched with EtOAc (30 mL), followed 
by addition of a saturated aqueous solution of NH4Cl (40 mL). The mixture was then 
allowed to warm to rt. The layers were separated, and the aqueous layer extracted with 
EtOAc (3 x 200 mL). The combined organic layers were washed with brine (400 mL), 
dried over Na2SO4, and concentrated under reduced pressure to afford a white solid. 
Purification on silica gel (0-20% EtOAc in hexanes) afforded 1.3 g of the lactone 3.S7 as 
a white crystalline solid (22% yield over 2 steps). 1H NMR (400 MHz, CDCl3): δ 6.78 (s, 
1H), 6.59 (m, 1H), 6.12 (s, 1H), 5.99 (dt, J = 15.7, 1.7 Hz, 1H), 5.28 (s, 2H), 5.16 (s, 2H), 
3.64 (s, 3H), 3.49 (s, 3H), 2.27 (s, 3H), 1.89 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, 
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CDCl3) δ 161.0, 159.2, 158.9, 152.2, 139.1, 131.6, 122.9, 122.3, 107.4, 105.1, 103.7, 
101.6, 94.2, 57.7, 56.4, 18.3, 9.9; HR-ESI-MS: m/z calculated for C17H21O6 [M+H]+: 






Lactone 3.S7 (1.0 g, 2.6 mmol, 1.0 equiv) in THF (13 mL) was stirred at -78 °C. DIBALH 
(0.48 mL, 2.7 mmol, 1.1 equiv) was added dropwise via syringe. The resulting solution 
was allowed to stir at -78 °C for 30 min, and then the reaction was quenched by the 
addition of EtOAc (1.0 mL) and Rochelle’s salt (saturated, 4.0 mL). The resulting mixture 
was stirred for 1 h at rt. The crude mixture was extracted with EtOAc (3 x 50 mL), and the 
combined organic layers were washed brine (20 mL), dried over Na2SO4, and 
concentrated under reduced pressure. Purification on silica gel (0-20% EtOAc in 
hexanes) afforded 730 mg of the lactol 3.S8 as a colorless oil (89% yield). 1H NMR (400 
MHz, CDCl3): δ 6.63 (s, 1H), 6.56 (d, J = 5.8 Hz, 1H), 6.33 (m, 1H), 5.97 (dd, J = 15.3, 
2.1 Hz, 1H), 5.78 (s, 1H), 5.16 (s, 2H), 5.01 (s, 2H), 3.60 (s, 3H), 3.45 (s, 3H), 2.15 (s, 
3H), 1.84 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 156.7, 153.0, 148.7, 129.1, 128.3, 126.0, 
119.0, 116.4, 105.8, 102.0, 99.9, 94.4, 89.0, 57.5, 56.0, 18.2, 9.9; HR-ESI-MS: m/z 
calculated for C17H23O6 [M+H]+: 323.1489, found: 323.1489; IR (thin film): 3357, 2930, 





Lactol 3.S8 (300 mg, 0.933 mmol) in MeCN and water (7:1, 0.04 M) was stirred at rt. 
LiBF4 (630 mg, 6.7 mmol, 7.2 equiv) was added and the resulting mixture was stirred at 
70 °C for 3 h. The reaction mixture was cooled to rt and quenched by the addition of water 
(15 mL). The mixture was diluted with EtOAc (30 mL) and the layers were separated. The 
aqueous layer was extracted with EtOAc (3 x 30 mL) and the combined organic layers 
were washed brine (40 mL), dried over Na2SO4, and concentrated under reduced 
pressure. Purification on silica gel (10-40% EtOAc in hexanes) afforded 200 mg (90% 
yield) of the title compound as a tan crystalline solid. 1H NMR (600 MHz, CD3OD) δ 9.77 
(s, 1H), 7.06 (m, 1H), 6.25 (d, J = 1.8 Hz, 1H), 6.22 (s, 1H), 4.12 (s, 2H), 2.00 (s, 3H), 
1.92 (d, J = 5.2 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ 197.5, 193.4, 163.7, 163.0, 144.8, 
138.0, 130.3, 112.3, 110.3, 109.9, 42.5, 17.0, 5.8; HR-ESI-MS: m/z calculated for 
C13H15O4 [M+H]+: 235.0965, found: 235.0947; IR (thin film): 3231, 2928, 2824, 2409, 














Prepared as previously reported by Baker Dockrey et al.22 
 
2,4-Dihydroxy-6-(4-hydroxy-2-oxopentyl)-3-methylbenzaldehyde (3.S12) 












26 (20 mg, 0.085 mmol, 1.0 equiv) and Au(OAc)3 (1.7 mg, 0.0043 mmol, 0.05 equiv) in 
DCE (0.94 mL) were added to a flame-dried vial. The mixture was stirred at rt for 30 min 
before IBX (28 mg, 0.10 mmol, 1.1 equiv), TBAI (19 mg, 0.051 mmol, 0.60 equiv), and 
TFA (0.094 mL, 10% total volume) were added. The mixture was stirred for an additional 
40 min before the reaction was quenched with 5 drops of a saturated Na2S2O3 solution. 
The mixture was filtered through a plug of ceilte, which washed with DCM, before the 
solution was concentrated under reduced pressure. Purification by preparative TLC with 
2.5% MeOH in DCM yielded 4.7 mg 5 (22% yield) of the title compound as an orange oil. 
1H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 6.59 (m, 1H), 6.10 (s, 1H), 6.01 (d, J = 15.6 
Hz, 1H), 5.58 (s, 1H), 1.94 (d, J = 7.0 Hz, 3H), 1.55 (s, 3H). All spectra obtained were 




Prepared as reported previously by Fuse et al.25 1.04 g (73% yield) of the title compound 
was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 5.24 (s, 1H), 1.98 (s, 3H), 1.68 






Prepared as reported previously by Franck and coworkers.11 356 mg (26% yield over 3 








To a solution of 3.5 (5.5 mg, 0.023 mmol, 1.0 equiv) and dioxinone 3.6 (5 mg, 0.035 mmol, 
1.5 equiv) in toluene (0.64 mL) in a flame dried vial under N2 was added mol sieves. The 
mixture was stirred at rt for 10 min and then heated to 110 °C. After 1 h, Et3N (0.0064 mL, 
0.046 mmol, 2.0 equiv) was added. The mixture was stirred for an additional hour at 110 
°C before it was cooled to room temperature and quenched with 1 M HCl (1.0 mL). The 
mixture was extracted with EtOAc (3 x 2.0 mL). The organic layers were combined, 
washed with brine, dried over Na2SO4, and concentrated under reduced pressure. 
Purification by preparative HPLC yielded 7.2 mg of 1 (>99% yield) as a yellow oil. 1H NMR 
(600 MHz, CDCl3) δ 8.82 (s, 1H), 6.63 (m, 1H), 6.06 (s, 1H), 6.01 (d, J = 13.8 Hz, 1H), 
5.35 (d, J = 1.2 Hz, 1H), 2.60 (s, 3H), 1.95 (d, J = 5.2 Hz, 3H), 1.69 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ 194.5, 190.0, 168.2, 165.6, 155.2, 153.1, 144.0, 136.3, 123.3, 122.3, 
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110.9, 107.5, 105.8, 87.6, 30.1, 29.7, 26.3, 18.7; HR-ESI-MS: m/z calculated for C17H15O5 
[M+H]+: 299.0914, found: 299.0922; IR (thin film): 2921, 2827, 1721, 1614, 1503 cm -1; 
[α]D +34 ° (c 0.1, CHCl3). All spectra obtained were consistent with literature values.13 
 
deflectin-1a (3.10) 
To a solution of 3.8 (4.0 mg, 0.019 mmol, 1.0 equiv) and dioxinone 3.9 (6.6 mg, 0.029 
mmol, 1.5 equiv) in toluene (0.55 mL) in a flame dried vial under N2 was added mol sieves. 
The mixture was stirred at rt for 10 min and then was heated to 110 °C. After 1 h, Et3N 
(53 μL, 0.038 mmol, 2.0 equiv) was added. The mixture was stirred for an additional hour 
at 110 °C before it was cooled to room temperature and quenched with 1 M HCl (1.0 mL). 
The mixture was extracted with EtOAc (3 x 2.0 mL) and the combined organic layers were 
washed with (5.0 mL), dried over Na2SO4, and concentrated under reduced pressure. 
Purification on silica gel (20% EtOAc in hexanes) yielded 5.9 mg of 3.10 (87% yield) as a 
yellow oil. 1H NMR (599 MHz, CDCl3) δ 8.77 (s, 1H), 6.08 (s, 1H), 5.28 (s, 1H), 3.16 (m, 
1H), 2.83 (m, 1H), 2.20 (s, 3H), 1.68 (s, 3H), 1.62 (m, 2H), 1.55 (s, 3H), 1.27 (m, 8H), 
0.87 (m, 3H); 13C NMR (151 MHz, CDCl3) δ 197.3, 190.3, 168.1, 165.2, 158.7, 153.3, 
144.1, 123.6, 111.1, 108.4, 104.9, 87.6, 42.1, 31.6, 29.0, 29.0, 26.2, 23.4, 22.6, 19.4, 
14.1; HR-ESI-MS: m/z calculated for C21H25O5 [M+H]+: 357.1697, found: 357.1754; IR 
(thin film): 2924, 1763, 1684, 1642 1540 cm-1; [α]D +88 ° (c 0.1, EtOAc). All spectra 




(2S,4S)-2,4-dimethylhexanoic acid (3.S13) 
Prepared as reported previously by Myers et al.19 278 mg (32% yield over 3 steps) of the 
title compound was obtained as a white crystalline solid. 1H NMR (599 MHz, CDCl3) δ 
2.56 (m, 1H), 1.72 (m, 1H), 1.39 (m, 1H), 1.32 (m, 1H), 1.17 (d, J = 7.0 Hz, 3H), 1.13 (m, 
2H), 0.88 (d, J = 6.6 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H). All spectra obtained were consistent 





To a solution of carboxylic acid 3.S13 (4.5 mg, 0.031 mmol, 1.1 equiv) in THF (0.2 mL) 
was added 2,4,6-trichlorobenzoyl chloride (0.0048mL, 0.031 mmol, 1.1 equiv) and Et3N 
(0.0043 mL, 0.031 mmol, 1.1 equiv). The mixture was stirred at rt for 30 min before it was 
filtered through celite and concentrated. The resulting clear oil was dissolved in toluene 
(0.8 mL) and added to 3.5 (6.5 mg, 0.028 mmol, 1 equiv) and DMAP (10.3 mg, 0.084 
mmol, 3 equiv). This mixture was stirred at 110 °C for 1 h before it was cooled to rt, 
acidified with a half-saturated solution of NH4Cl (1 mL), and extracted with EtOAc. The 
organic layers were washed with brine, dried over Na2SO4, and concentrated under 
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reduced pressure. Purification on silica gel (10-30% EtOAc in hexanes) provided 5 mg 
(50% yield) of the title compound as an orange oil. 1H NMR (400 MHz, CDCl3) δ 7.88 (s, 
1H), 6.55 (m, 1H), 6.07 (s, 1H), 6.00 (d, J = 15.0 Hz, 1H), 5.57 (s, 1H), 2.70 (m, 1H), 1.93 
(d, J = 6.9 Hz, 3H), 1.77 (m, 1H), 1.53 (s, 3H), 1.34 (m, 2H), 1.19 (d, J = 6.9 Hz, 3H), 1.13 
(m, 2H), 0.89 (m, 6H). 13C NMR (151 MHz, CDCl3) δ 193.2, 192.7, 176.3, 155.3, 153.4, 
142.6, 135.3, 122.4, 114.9, 108.5, 107.8, 83.8, 40.8, 36.2, 31.8, 29.4, 22.1, 19.1, 18.6, 
17.6, 11.1; HR-ESI-MS: m/z calculated for C21H27O5 [M+H]+: 359.1853, found: 359.1858; 




isochromen-7-yl (2S,4S)-2,4-dimethylhexanoate (3.14)  
To a solution of 3.12 (5.5 mg, 0.015 mmol, 1 equiv) and methyl acrylate (5.4 µL, 0.060 
mmol, 4.0 equiv) in degassed DCM (0.6 mL) was added a solution of Grubbs Catalyst 2nd 
generation (2.5 mg, 0.0030 mmol, 0.20 equiv) in degassed DCM (0.5 mL). The mixture 
was stirred at 45 °C for 4 h before it was cooled to rt and concentrated. Purification on 
silica gel (10-35% EtOAc in hexanes) afforded 2.6 mg (48% yield) of the title compound 
as a yellow glass. 1H NMR (400 MHz, CDCl3) δ 7.88 (s, 1H), 7.13 (d, J = 15.6 Hz, 1H), 
6.52 (d, J = 15.6 Hz, 1H), 6.45 (s, 1H), 5.69 (s, 1H), 3.82 (s, 3H), 2.69 (m, 1H), 1.75 (m, 
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1H), 1.53 (s, 3H), 1.29 (m, 2H), 1.19 (d, J = 6.8 3H), 1.13 (m, 2H), 0.89 (m, 6H). 13C NMR 
(201 MHz, CDCl3) δ 192.8, 192.5, 165.8, 153.2, 153.1, 152.7, 140.7, 133.5, 124.0, 115.8, 
114.9, 110.5, 83.8, 52.3, 40.8, 36.2, 31.8, 29.5, 21.9, 19.1, 17.6, 11.1; HR-ESI-MS: m/z 
calculated for C22H27O6: 403.1751, found: 403.1728; IR (thin film): 2926, 2853, 1718, 
1630, 1454 cm-1. [α]D -12.2 ° (c 0.1, CHCl3). All spectra obtained were consistent with 
literature values.16 
 
II. Biocatalytic Reactions 
Stock solutions: Stock solutions of each substrate (50 mM) were prepared by dissolving 
the substrate in DMSO (analytical grade). Stock solutions of NADP+ (100 mM) and 
glucose-6-phosphate (G6P, 500mM) were stored at -20 °C. Aliquots of each flavin-
dependent enzyme and glucose-6-phosphate dehydrogenase (G6PDH, 100 U/mL) were 
stored at -80 °C. Analytical-scale reactions: Each reaction contained 25 μL 100 mM 
potassium phosphate buffer, pH 8.0, 2.5 mM substrate (2.5 μL of a 50 mM stock solution 
in DMSO), 5-20 μM flavin-dependent monooxygenase, 5 mM G6P (0.5 μL, 500 mM), 1 
mM NADP+ (0.5 μL, 100 mM), 1 U/mL G6P-DH (0.5 μL, 100 U/mL), and Milli-Q water to 
a final volume of 50 μL. The reaction was carried out at 30 °C for 1 h and quenched by 
addition of 75 µL acetonitrile with 25 mM pentamethylbenzene as an internal standard. 
Precipitated biomolecules were pelleted by centrifugation (16,000 x g, 12 min). The 
supernatant was analyzed by UPLC-DAD and conversion obtained by comparison to 
calibration curves of each substrate. The subsequent liquid chromatography PDA 
spectrometry (UPLC) analysis was performed on a Waters Aquity H-Class UPLC-PDA 
using a Phenomenex Kinetex 1.7 µm C18, 2.1x150 mm column under the following 
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conditions: Method A: mobile phase (A = deionized water + 0.1% formic acid, B = 
acetonitrile + 0.1% formic acid), 5% to 100% B over 1.5 min, 100% B for 1.0 min; flow 
rate, 0.5 mL/min; Method B: mobile phase (A = deionized water + 0.1% formic acid, B = 
acetonitrile + 0.1% formic acid), 5% to 100% B over 2 min, 100% B for 1 min; flow rate, 
0.5 mL/min. Based on calibration curves of the starting materials, the percent conversion 
of the substrate to dearomatized product was calculated with AUCsubstrate/AUCinternal 
standard at 270 nm. All reactions were performed and analyzed in triplicate.  
 
General procedure for in vitro preparative-scale reactions: Preparative–scale 
enzymatic reactions were conducted on 20 mg of each substrate under the following 
conditions: 5-20 µM flavin-dependent monooxygenase, 2.5 mM substrate, 1 mM NADP+, 
1 U/mL G6PDH, and 5 mM G6P for NADPH generation in reaction buffer (50 mM 
potassium phosphate buffer, pH 8.0). The reaction mixture was added to a 50 mL 
Erlenmeyer flask and incubated at 30 °C with 100 rpm shaking. After 2 h, a 50 µL aliquot 
was removed and processed in an identical manner to the analytical-scale reactions 
described above to determine substrate conversion. The remaining reaction mixture was 
diluted with acetone (2 x total reaction volume). Precipitated biomolecules were pelleted 
by centrifugation (4,000 x g, 12 min). Isolation procedure: The supernatant was 
concentrated under reduced pressure to a final volume of approximately 2 mL. The 
resulting mixture was filtered through a 0.22 µm filter and purified by preparative HPLC 
using a Phenomenex Kinetex 5 µm C18, 150 x 21.2 mm column under the following 
conditions: mobile phase A = deionized water + 0.1% formic acid and B = acetonitrile + 
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The title compound was synthesized using AzaH according to the general procedure for 
milligram-scale in vitro enzymatic oxidative dearomatization and isolated using the 
general isolation method. Purification by preparative HPLC afforded 9.6 mg  (96%  yield) 
of the title compound as a yellow oil. 1H NMR (400 MHz, CDl3) δ 7.89 (s, 1H), 6.59 (m, 
1H), 6.10 (s, 1H), 6.01 (d, J = 15.6 Hz, 1H), 5.57 (s, 1H), 2.62 (s, 2H), 1.94 (d, J = 7.0 Hz, 





The title compound was synthesized using AfoD according to the general procedure for 
milligram-scale in vitro enzymatic oxidative dearomatization and isolated using the 
general isolation method. Purification by preparative HPLC afforded 4 mg (83% yield) of 
the title compound as a yellow oil. 1H NMR (400 MHz, CDl3) δ 7.89 (s, 1H), 6.59 (m, 1H), 
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6.10 (s, 1H), 6.01 (d, J = 15.6 Hz, 1H), 5.57 (s, 1H), 2.62 (s, 2H), 1.94 (d, J = 7.0 Hz, 3H), 
1.55 (s, 3H). All spectra obtained were consistent with reported values.9 
 
(R)-7-hydroxy-3,7-dimethyl-6H-isochromene-6,8(7H)-dione (3.8) 
The title compound was synthesized using AzaH according to the general procedure for 
milligram-scale in vitro enzymatic oxidative dearomatization and isolated using the 
general isolation method. Purification by preparative HPLC afforded 9.5 mg (95% yield) 
of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.88 (s, 1H), 7.26 (s, 
2H), 6.13 (s, 1H), 5.51 (s, 1H), 2.20 (s, 3H), 1.55 (s, 3H). All spectra obtained were 




































































IV. UPLC Traces of Biotransformations 
Figure 3.3. Oxidative dearomatization of 3.S12 by AfoD and AzaH. PDA traces of 
enzymatic reaction and control reaction. (Table 3.1, entry 2). SM = starting material, INT 
= intermediate, PRD = product, IS = internal standard. The anionic form of the 































 Retention Time Area % Area Height 
1 0.563 258810 70.42 220721 
2 2.967 108693 29.58 78693 
 Retention Time Area % Area Height 
1 1.988 174634 54.03 55311 
2 2.254 41199 12.75 44106 







































































































Figure 3.4. Oxidative dearomatization of 3.S9 by AfoD and AzaH. PDA traces of 





 Retention Time Area % Area Height 
1 2.110 305704 76.28 183131 


































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.241 292664 74.92 268642 
2 2.970 97969 25.08 66721 
9 Retention Time Area % Area Height 
1 2.126 111917 29.11 83638 
2 2.428 171664 44.65 146387 

















































































































 Retention Time Area % Area Height 
1 2.426 301558 76.61 252996 
2 2.955 92051 23.39 63755 
 
 
Figure 3.5. Oxidative dearomatization of 3.S11 by AfoD and AzaH. PDA traces of 




 Retention Time Area % Area Height 
1 2.357 517469 65.70 351986 
2 2.652 176051 22.35 140720 
3 2.957 94126 11.95 65187 
With AfoD 
  
 Retention Time Area % Area Height 
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Figure 3.6. Oxidative dearomatization of 3.S2 by AfoD and AzaH. PDA traces of 





 Retention Time Area % Area Height 
1 2.054 944560 91.63 354150 
2 2.956 86293 8.37 59688 
With AfoD 
 
 Retention Time Area % Area Height 










































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.650 266100 74.22 214826 

























































































 Retention Time Area % Area Height 
1 2.453 321740 77.09 237334 
2 2.953 95619 22.91 65898 
 
Figure 3.7. Oxidative dearomatization of 3.S3 by AfoD and AzaH. PDA traces of 































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 0.565 434990 83.72 338239 












































 Retention Time Area % Area Height 
1 0.572 113995 30.42 89263 
2 2.271 157150 41.94 133701 






























































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.270 284197 77.11 250475 
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Figure 3.8. Oxidative dearomatization of 3.7 by AfoD and AzaH. PDA traces of 
enzymatic reaction and control reaction. (Table 3.1, entry 7). 
 
With AzaH  
  
 Retention Time Area % Area Height 
1 2.119 519413 77.67 69861 
2 2.376 60100 8.99 56370 




 Retention Time Area % Area Height 
1 2.147 398043 65.96 84339 
2 2.377 119827 19.86 97170 























































































220.00 240.00 260.00 280.00 300.00 320.00 340.00 360.00 380.00
 Retention Time Area % Area Height 
1 2.378 383633 81.55 308926 
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Figure 3.9. Oxidative dearomatization of 3.4 by AfoD and AzaH. PDA traces of 
enzymatic reaction and control reaction. (Table 3.1, entry 6). Two wavelengths are 
shown to visualize product. 
 
With AzaH  
 
 
 Retention Time Area % Area Height 
1 1.946 59575 25.80 32920 
2 2.074 40004 17.33 21701 





 Retention Time Area % Area Height 
1 1.946 59575 25.80 32920 
















































































































































































 Retention Time Area % Area Height 
1 2.063 507851 79.50 208715 


























































































V. Determination of Enantiomeric Excess 
 
Figure 3.10. PDA traces of racemic 3.5 obtained from a 1:1 mixture of the compound 
generated using AzaH and AfoD, (S)- 3.5 obtained from AfoD-mediated oxidative 
dearomatization, (R)- 3.5 obtained from AzaH-mediated oxidative dearomatization 








Figure 3.11. PDA traces of racemic 3.8 obtained from an IBX-mediated oxidative 
dearomatization, (S)- 3.8 obtained from AfoD-mediated oxidative dearomatization, (R)- 
3.8 obtained from AzaH-mediated oxidative dearomatization (CHIRALPAK® AD-H, 





































































































































































































VII. Single-Crystal Structure Determination  
Single-crystal X-ray diffraction data were collected using a Rigaku XtaLAB Synergy-S X-
ray diffractometer configured in a kappa goniometer geometry. The diffractometer is 
equipped with a PhotonJet-S microfocus Cu source (λ = 1.54187 Å) set at a rough 
divergence of 9.5 and operated at 50 kV and 1 mA. X-ray intensities were measured at 
298(1) K with the HyPix-6000HE detector placed 34.00 mm from the sample. The data 
were processed with CrysAlisPro v38.46 (Rigaku Oxford Diffraction) and corrected for 
absorption. The structures were solved in OLEX226 using SHELXTL27 and refined using 
SHELXL.28 All non-hydrogen atoms were refined anisotropically with hydrogen atoms 
placed at idealized positions. 
 
Table 3.2 Crystallographic parameters for trichoflectin 
 
Material exp_589 
Space Group P212121 
a Å 5.39440(6) 
b Å 18.0328(2) 
c Å 29.9372(4) 
Volume (Å3) 2912.18 
Flack 0.00(6) 
Temperature 298(1) 














Figure 3.12. A view of exp_589 showing the atom labelling scheme. Thermal ellipsoids 













VIII. Circular Dichroism Spectroscopy of Azaphilones 3.1, 3.10, 3.14 
 
Instruments and methods 
 
Circular dichroism (CD) spectra were collected on a J-1500 Circular Dichroism 
Spectrophotometer (Jasco). Samples were prepared in UPLC grade MeCN at a final 
concentration of 750 μM. Data points were collected at room temperature from 190 to 500 




The general approach for absolute configuration assignment using ECD, including the 
detailed computational workflow, has been published elsewhere.29-31 A subset of the 
details of the computational methodology is provided here. Conformers of each test 
structure were geometry optimized at the B3LYP/6-31G** level and stationary points were 
confirmed by performing frequency calculations.32-40 All calculations were performed 
using Gaussian 09.41 Output conformers were ranked according to DFT energy and a 
clustering was performed in order to remove duplicates. Initial duplicate identification was 
performed solely on an electronic energy basis where two compounds were considered 
identical if the difference in Hartrees was less than 0.01. Rounding the differences led to 
inconsistencies in identification of duplicates. It became better to cluster the DFT minima 
by energy and then re-cluster each energy bucket by structure using an all atom RMS of 
0.6 Å. This process removed just identical compounds. Two Boltzmann distributions were 
calculated based on the free energy (G) and the electronic energy (E). 
To calculate UV and ECD spectra, B3LYP geometries were used as input.  The spectra 
were then calculated using either the B3LYP or CAM-B3LYP42 functionals, along with the 
6-31++G** basis set43, 44 in vacuo. Only conformers which contributed more than 5.0% to 
the total in vacuo conformer distribution were selected for UV and ECD calculation. Time-
dependent Density Functional Theory (TDDFT)45 methodology was employed using the 
following keywords: TD=full,singlet, Nstates=100, and integral=ultrafinegrid. Spectral 
display, Boltzmann weighting, and curve fitting were carried out using SpecDis,46, 47 and 
were displayed with a wavelength shift and band broadening sigma values in order to 
best match the calculated and experimental UV spectra.  This shift and band broadening 




Calculations of the ECD and UV spectra (CAM-B3LYP/6-31++G**) involved modeling the 
(R)- enantiomer of the natural product.  Since no other stereoisomers were possible, it 
should be noted that the (S)-enantiomer is assumed to have a spectrum that will be equal 
and opposite at all wavelengths. 
 Figure S22 provides an overlay of the calculated and measured UV and ECD spectra 
using the theoretical spectrum of the (R)-enantiomer.  The calculated spectrum has been 
shifted 30 nm and a band broadening of σ=0.39 eV applied in order to optimize the UV 
spectral match.  A high degree of confidence is derived from the statistical and visual 
matching of the spectra, with the experimental spectrum matching the mirror image of the 
135 
 
calculated (R)-enantiomer.  Hence, the absolute configuration of trichoflectin can 
confidently be assigned as (S). Figure S23 shows the one conformer of the (R) 
enantiomer that contributed >5% to the Boltzmann weighted spectrum, and the 
coordinates of this conformer are shown with the electronic energy below.  Assigned 
absolute configuration of the desired compounds is provided in Scheme S1. 
 
Figure 3.13.  Comparison between experimental (black) and calculated (red) UV (top) 
and ECD (bottom) spectra.  The calculated (R)-enantiomer is opposite of the 
experimental spectrum, with a large difference in fits (Δ=0.8857) suggesting a confident 
assignment.  The calculated spectrum has been shifted 30 nm, and a band broadening 











Figure 3.15. One conformer of the (R)-enantiomer of trichoflectin that contributes >5% 
to the Boltzmann distribution.  Note the percentage shown above based is on in vacuo  
electronic energies. 
 
Coordinates and electronic energies for B3LYP/6-31G** conformational minima 
contributing >5% to the in vacuo Boltzmann distribution. 
 
      Conformer 1: -1032.346471 hartrees        
z 
6 -1.92652 -1.24179 0.454749 
6 -1.43886 -2.36436 -0.50656 
6 -0.00398 -2.37628 -0.72861 
6 0.811717 -1.3366 -0.3621 
6 0.287916 -0.07181 0.177876 
6 -1.16113 0.044932 0.262781 
6 1.15752 0.916672 0.51399 
6 2.24341 -1.37366 -0.51756 
8 -2.21691 -3.20925 -0.91931 
6 3.04043 -0.3412 -0.14027 
6 4.48685 -0.31902 -0.24494 
8 2.49748 0.804537 0.396205 
6 5.27154 0.705286 0.129229 
6 -2.0555 1.05447 0.067487 
6 -3.41789 0.444905 0.026975 
8 -3.29409 -0.90399 0.221383 
6 -1.79661 2.49736 -0.17149 
8 -0.75437 3.01999 0.214502 
8 -4.4906 0.97176 -0.14711 
6 6.76245 0.716682 0.01421 
6 -2.84313 3.30205 -0.90379 
6 -1.81538 -1.7794 1.89715 
1 7.0976 1.54991 -0.61613 
1 7.1483 -0.21358 -0.41144 
1 7.22791 0.866265 0.996514 
1 -2.48918 4.32822 -1.00616 
1 -3.79449 3.26342 -0.3666 
1 -3.0406 2.8698 -1.89086 
1 -2.17304 -1.0227 2.60047 
1 -0.78389 -2.04131 2.14313 
1 -2.44014 -2.67163 1.98075 
1 0.408491 -3.25877 -1.20725 
1 0.849272 1.88074 0.892321 
1 2.70889 -2.25918 -0.93574 
1 4.92704 -1.22041 -0.66473 




Lunatoic Acid A Methyl Ester (3.14) 
Calculations of the ECD and UV spectra (CAM-B3LYP/6-31++G**) involved 
modeling the (R)  enantiomer of the natural product methyl ester.  While the compound 
contains an ester chain with two stereocenters, the majority of the UV absorption and thus 
the ECD signal is expected to come from the stereocenter on the ring.  Calculations of a 
hypothetical diastereomer with inversion at the stereocenter alpha to the ester carbonyl 
showed an analogous signal to that for the expected structure, indicating that this prior 
assumption is correct.  
 Figure S26 provides overlays of the calculated and measured UV and ECD 
spectra using the theoretical spectrum of the (R)-enantiomer.  The calculated spectrum 
has been shifted -46 nm and a band broadening of σ=0.28 eV applied in order to optimize 
the UV spectral match.  A high degree of confidence is derived from the statistical and 
visual matching of the spectra, with the experimental spectrum matching the calculated 
(R)-enantiomer.  Hence, the absolute configuration of the methyl ester of Lunatoic Acid A 
can confidently be assigned as (R). Figure S27 shows the six conformers of the (R) 
enantiomer that contributed >5% to the Boltzmann weighted spectrum, and the 
coordinates of these conformers are shown with the electronic energies listed below.  
Assigned absolute configuration of the desired compounds is provided in Scheme S2. 
 
 
Figure 3.16.  Comparison between experimental (black) and calculated (red) UV (top) and ECD 
(bottom) spectra.  The calculated (R)-enantiomer is a good match to the experimental, with a 
large difference in fits (Δ=0.6677) suggesting a confident assignment.  The calculated spectrum 





Figure 3.17. Assigned absolute configuration of lunatoic acid A methyl ester based on ECD 
analysis.  
 
Figure 3.18. Six conformers of the (R)-enantiomer of lunatoic acid A methyl ester that contribute 




Coordinates and electronic energies for B3LYP/6-31G** conformational minima 
contributing >5% to the in vacuo Boltzmann distribution. 
 
 
       Conformer 1: -1380.662338 hartrees        
z 
6 1.78282 -1.68543 0.941074 
6 1.32039 -2.58496 -0.23991 
6 -0.08437 -2.56709 -0.60377 
6 -0.9426 -1.60841 -0.14681 
6 -0.5196 -0.5554 0.767273 
6 0.874425 -0.48446 1.26383 
6 -2.32929 -1.52556 -0.54115 
6 -3.1488 -0.54276 -0.08739 
8 -2.69057 0.431987 0.778282 
6 -1.39911 0.390925 1.16506 
6 -4.54266 -0.40614 -0.4433 
6 -5.36122 0.565606 -0.00381 
6 -6.77309 0.588333 -0.44821 
8 -7.42645 1.63913 0.094655 
8 -7.29006 -0.21849 -1.19745 
6 -8.81115 1.75329 -0.27781 
8 1.27673 0.428157 1.96608 
8 2.14123 -3.32308 -0.7703 
6 1.88912 -2.55832 2.19714 
8 3.11592 -1.21925 0.681905 
6 3.21769 -0.42005 -0.4067 
6 4.65684 -0.13761 -0.77387 
8 2.24322 -0.05119 -1.03495 
6 4.86859 1.32854 -1.19008 
6 5.00568 2.33153 -0.02596 
6 3.77038 2.4135 0.898726 
6 5.40257 3.71242 -0.57045 
6 5.00231 -1.11961 -1.91571 
6 2.48952 2.96521 0.26043 
1 -9.18284 2.6388 0.236805 
1 -9.36624 0.864184 0.032778 
1 -8.90866 1.86616 -1.36077 
1 2.26945 -1.95226 3.02238 
1 2.57353 -3.38374 1.99027 
1 0.910116 -2.96483 2.46741 
1 5.50425 4.44226 0.240151 
1 4.65198 4.09497 -1.27036 
1 6.35778 3.66779 -1.10507 
1 6.06683 -1.05241 -2.15839 
1 4.42381 -0.8727 -2.81099 
1 4.76711 -2.14983 -1.63287 
1 1.67012 2.92449 0.983973 
1 2.60967 4.00572 -0.05882 
1 2.18371 2.37216 -0.60516 
1 4.05069 1.6223 -1.85843 
1 5.78692 1.37485 -1.78889 
1 4.0386 3.04453 1.75683 
1 3.55559 1.42696 1.32415 
1 5.27726 -0.37544 0.096936 
1 5.83819 1.97483 0.600279 
1 -0.4089 -3.31549 -1.31925 
1 -2.73808 -2.26244 -1.22363 
1 -1.13259 1.20076 1.8328 
1 -4.9434 -1.15583 -1.12031 
1 -5.02585 1.34477 0.670543 
 
 
       Conformer 2: -1380.662034 hartrees        
z 
6 1.60301 -0.03006 1.10298 
6 1.3789 -1.37343 0.355659 
6 0.014003 -1.7783 0.076571 
6 -1.04379 -0.9249 0.210908 
6 -0.88031 0.452365 0.656243 
6 0.458903 0.995158 0.987229 
6 -2.40696 -1.28817 -0.0968 
6 -3.43234 -0.40746 0.032594 
8 -3.21705 0.887649 0.463061 
6 -1.95435 1.26785 0.747312 
6 -4.81605 -0.71065 -0.25362 
6 -5.83805 0.154289 -0.13215 
6 -7.21264 -0.28798 -0.45871 
8 -8.09295 0.721015 -0.27846 
8 -7.52427 -1.40097 -0.83766 
6 -9.4627 0.393566 -0.57157 
8 0.650022 2.17255 1.23702 
8 2.3459 -2.0847 0.107215 
6 1.81116 -0.3468 2.59071 
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8 2.82306 0.578009 0.669392 
6 2.82824 0.976139 -0.62908 
6 4.13858 1.63788 -1.00285 
8 1.86405 0.836693 -1.35396 
6 5.34521 0.822473 -0.50325 
6 5.39588 -0.62932 -1.02382 
6 6.2899 -1.51713 -0.1358 
6 5.85781 -0.67645 -2.48719 
6 4.13868 3.07093 -0.43476 
6 5.70701 -1.793 1.25639 
1 -10.0311 1.3026 -0.37759 
1 -9.80742 -0.42213 0.069435 
1 -9.56843 0.086968 -1.61553 
1 2.01622 0.581948 3.12786 
1 2.65955 -1.02784 2.68593 
1 0.921112 -0.82186 3.01336 
1 5.82731 -1.6996 -2.87624 
1 6.88894 -0.31306 -2.58176 
1 5.22695 -0.06024 -3.13642 
1 5.05623 3.58945 -0.72908 
1 4.0866 3.04841 0.657594 
1 3.2833 3.64439 -0.80353 
1 6.33759 -2.49318 1.81458 
1 5.62542 -0.87924 1.85454 
1 4.70273 -2.219 1.16926 
1 5.31673 0.82973 0.590032 
1 6.26441 1.34783 -0.79631 
1 7.28637 -1.05919 -0.04828 
1 6.44131 -2.47593 -0.64853 
1 4.13371 1.68799 -2.09586 
1 4.38433 -1.05266 -0.96904 
1 -0.12316 -2.78673 -0.29964 
1 -2.63015 -2.2909 -0.44405 
1 -1.88497 2.30284 1.05848 
1 -5.02839 -1.72114 -0.59244 
1 -5.69587 1.17646 0.198431 
 
 
      Conformer 3: -1380.661580 hartrees___         
6 1.80645 -1.44169 0.96146 
6 1.25025 -2.64964 0.155399 
6 -0.17932 -2.70503 -0.09509 
6 -0.9995 -1.63538 0.118238 
6 -0.5044 -0.36532 0.63408 
6 0.927277 -0.17683 0.961251 
6 -2.41536 -1.64472 -0.16665 
6 -3.19794 -0.55479 0.039268 
8 -2.67158 0.624928 0.532123 
6 -1.35133 0.67509 0.80152 
6 -4.61807 -0.50162 -0.22184 
6 -5.40103 0.573276 -0.02404 
6 -6.84641 0.491423 -0.33301 
8 -7.45656 1.66853 -0.07229 
8 -7.42178 -0.4906 -0.76212 
6 -8.86935 1.69464 -0.34157 
8 1.38571 0.902317 1.30141 
8 2.02181 -3.54237 -0.16765 
6 2.00108 -1.88773 2.41606 
8 3.1193 -1.11135 0.482608 
6 3.14307 -0.63909 -0.78697 
6 4.53741 -0.2664 -1.24181 
8 2.13028 -0.48912 -1.44328 
6 4.66904 1.27368 -1.1446 
6 4.59209 1.85383 0.282993 
6 4.31946 3.37107 0.257395 
6 5.87038 1.54384 1.07516 
6 4.76159 -0.76217 -2.67659 
6 2.91313 3.7473 -0.22612 
1 -9.20045 2.69967 -0.08196 
1 -9.389 0.947829 0.264516 
1 -9.06233 1.48472 -1.39691 
1 2.44538 -1.06879 2.98614 
1 2.66392 -2.75546 2.42639 
1 1.04297 -2.16464 2.86562 
1 5.79709 1.92248 2.1002 
1 6.74457 2.01411 0.607319 
1 6.06246 0.46803 1.13768 
1 5.75721 -0.4714 -3.02445 
1 4.01456 -0.32844 -3.34689 
1 4.67943 -1.85142 -2.73795 
1 2.74341 4.82575 -0.13886 
1 2.75264 3.47711 -1.27494 
1 2.15184 3.22853 0.365762 
1 3.87972 1.70055 -1.77273 
1 5.62504 1.56475 -1.60085 
1 5.07915 3.86872 -0.36329 
141 
 
1 4.4569 3.76179 1.27411 
1 5.25224 -0.74403 -0.56586 
1 3.74888 1.38755 0.806291 
1 -0.55972 -3.62808 -0.52008 
1 -2.87746 -2.54332 -0.56017 
1 -1.03229 1.64273 1.16855 
1 -5.07182 -1.41047 -0.60798 
1 -5.01289 1.51069 0.356631 
 
 
      Conformer 4: -1380.661272 hartrees___   
6 -1.55596 0.525882 -1.24688 
6 -1.39326 -1.0005 -1.00539 
6 -0.05116 -1.52379 -0.8291 
6 1.02845 -0.71386 -0.622 
6 0.913797 0.737612 -0.57223 
6 -0.39731 1.40781 -0.74319 
6 2.36829 -1.20795 -0.4078 
6 3.41619 -0.37277 -0.18895 
8 3.24754 0.998342 -0.15597 
6 2.00729 1.49677 -0.33804 
6 4.77861 -0.80378 0.026419 
6 5.82249 0.014168 0.247073 
6 7.1711 -0.5609 0.452202 
8 8.07907 0.417463 0.662086 
8 7.44234 -1.74653 0.437014 
6 9.42675 -0.03819 0.875153 
8 -0.55242 2.60508 -0.57627 
8 -2.38406 -1.71879 -1.06503 
6 -1.70204 0.748363 -2.75855 
8 -2.78252 0.991689 -0.67293 
6 -2.83081 0.930493 0.682381 
6 -4.13767 1.4721 1.21872 
8 -1.908 0.500183 1.34539 
6 -5.34191 0.698497 0.642041 
6 -5.24923 -0.83741 0.727787 
6 -6.51003 -1.46636 0.103601 
6 -5.01215 -1.3188 2.16701 
6 -4.23525 2.97921 0.918661 
6 -6.4124 -2.97899 -0.12288 
1 10.0219 0.861883 1.02621 
1 9.78444 -0.5968 0.006194 
1 9.47759 -0.68702 1.75349 
1 -1.86965 1.81069 -2.94948 
1 -2.55413 0.164679 -3.11348 
1 -0.80108 0.422162 -3.28621 
1 -4.9906 -2.41061 2.22314 
1 -5.8082 -0.96452 2.83488 
1 -4.05431 -0.96166 2.55624 
1 -5.1559 3.38547 1.34882 
1 -4.2481 3.15507 -0.1603 
1 -3.38633 3.52528 1.3407 
1 -7.29867 -3.35722 -0.64326 
1 -5.53364 -3.22271 -0.73012 
1 -6.32747 -3.52973 0.819164 
1 -5.46021 0.98631 -0.40951 
1 -6.24213 1.04551 1.16859 
1 -6.70048 -0.97928 -0.86224 
1 -7.38038 -1.23849 0.736557 
1 -4.08389 1.32562 2.30077 
1 -4.39419 -1.15298 0.115844 
1 0.047924 -2.60425 -0.81956 
1 2.55469 -2.27614 -0.41827 
1 1.97342 2.57747 -0.27647 
1 4.9545 -1.87597 0.005158 
1 5.71658 1.09205 0.282637 
 
 
      Conformer 5: -1380.661154 hartrees___ 
6 -1.70828 -1.20718 -1.044 
6 -1.12066 -2.5505 -0.52456 
6 0.316767 -2.63888 -0.33668 
6 1.12181 -1.53681 -0.34376 
6 0.599747 -0.19309 -0.55821 
6 -0.846 0.041816 -0.78461 
6 2.54702 -1.58687 -0.11521 
6 3.3148 -0.46736 -0.11168 
8 2.76371 0.782449 -0.32434 
6 1.43357 0.870572 -0.52933 
6 4.74316 -0.45144 0.10636 
6 5.51166 0.651664 0.116227 
6 6.96763 0.525948 0.352105 
8 7.56038 1.74003 0.329591 
8 7.56432 -0.51695 0.541498 
6 8.98158 1.72773 0.551402 
8 -1.3222 1.16282 -0.85634 
142 
 
8 -1.87601 -3.50042 -0.37132 
6 -1.91367 -1.33244 -2.55985 
8 -3.0199 -1.01853 -0.49685 
6 -3.04852 -0.83734 0.847156 
6 -4.45833 -0.65166 1.36568 
8 -2.03566 -0.79038 1.51714 
6 -4.77348 0.863851 1.43291 
6 -4.66903 1.65075 0.111329 
6 -4.92025 3.14662 0.387374 
6 -5.61908 1.09458 -0.95946 
6 -4.59634 -1.31114 2.74352 
6 -4.59509 4.06869 -0.79281 
1 9.29665 2.76957 0.502455 
1 9.48449 1.13527 -0.21748 
1 9.21301 1.29956 1.53026 
1 -2.38161 -0.4191 -2.93419 
1 -2.56102 -2.19071 -2.75188 
1 -0.95718 -1.48515 -3.06813 
1 -5.57012 1.68249 -1.88047 
1 -6.65876 1.11124 -0.6076 
1 -5.3616 0.065677 -1.22357 
1 -5.60462 -1.15335 3.13773 
1 -3.87404 -0.88278 3.44345 
1 -4.41277 -2.38806 2.68718 
1 -4.71353 5.12105 -0.51411 
1 -3.56092 3.92231 -1.12436 
1 -5.2485 3.88323 -1.65103 
1 -4.09515 1.31017 2.17161 
1 -5.79004 0.969011 1.83696 
1 -4.30819 3.45048 1.24707 
1 -5.9671 3.28843 0.693539 
1 -5.138 -1.13152 0.656004 
1 -3.64387 1.55535 -0.2667 
1 0.7176 -3.6258 -0.13015 
1 3.02866 -2.54208 0.062222 
1 1.09511 1.88971 -0.66938 
1 5.21619 -1.41532 0.274219 
1 5.10413 1.64318 -0.04225 
 
 
      Conformer 6: -1380.660826 hartrees___ 
6 1.72315 -1.62726 1.01081 
6 1.24166 -2.62238 -0.08242 
6 -0.16608 -2.619 -0.43605 
6 -1.00892 -1.61352 -0.05807 
6 -0.56392 -0.48662 0.75176 
6 0.838572 -0.38436 1.22068 
6 -2.3998 -1.55165 -0.44166 
6 -3.2047 -0.52476 -0.06623 
8 -2.72664 0.518295 0.70386 
6 -1.42978 0.499758 1.0748 
6 -4.60218 -0.40712 -0.41468 
6 -5.40691 0.606813 -0.05153 
6 -6.82459 0.603336 -0.47743 
8 -7.46216 1.70327 -0.01965 
8 -7.35838 -0.26105 -1.14638 
6 -8.85109 1.79673 -0.38191 
8 1.26131 0.588955 1.82173 
8 2.04829 -3.41738 -0.54816 
6 1.80693 -2.38374 2.34257 
8 3.06546 -1.2171 0.716302 
6 3.19106 -0.52486 -0.44267 
6 4.6419 -0.30463 -0.81074 
8 2.23111 -0.19526 -1.11171 
6 4.86933 1.08758 -1.42272 
6 4.94597 2.25717 -0.4196 
6 3.68055 2.36787 0.452821 
6 5.23967 3.55856 -1.18128 
6 5.00999 -1.43674 -1.79549 
6 3.69924 3.51074 1.47278 
1 -9.20878 2.72677 0.058749 
1 -9.40842 0.942826 0.012222 
1 -8.96316 1.81602 -1.46917 
1 2.19988 -1.71345 3.11027 
1 2.47304 -3.23965 2.2149 
1 0.818603 -2.74182 2.64538 
1 5.42632 4.39555 -0.50293 
1 4.39167 3.82928 -1.82237 
1 6.1209 3.45106 -1.82334 
1 6.08112 -1.40892 -2.01595 
1 4.45828 -1.31408 -2.73249 
1 4.75794 -2.4165 -1.37973 
1 2.8286 3.4425 2.13228 
1 4.59742 3.46547 2.10064 
1 3.67856 4.49506 0.994432 
1 4.06901 1.27588 -2.14954 
143 
 
1 5.80757 1.0558 -1.99064 
1 3.53263 1.43619 1.00763 
1 2.80314 2.46653 -0.19955 
1 5.23904 -0.42073 0.100448 
1 5.79589 2.06093 0.254076 
1 -0.50645 -3.42507 -1.07773 
1 -2.82413 -2.34211 -1.05077 
1 -1.14669 1.36374 1.6632 
1 -5.01815 -1.20969 -1.01787  
1 -5.05606 1.43894 0.547458 
Deflectin-1a (3.10) 
Calculations of the ECD and UV spectra (B3LYP/6-31++G**) involved modeling the truncated (R) 
enantiomer of the natural product, shortening the exocyclic alkyl chain to a propyl group.  This way there 
was still some conformational flexibility, but at a reduced computational cost.  Since no other stereoisomers 
were possible, it should be noted that the (S)-enantiomer is assumed to have a spectrum that will be equal 
and opposite at all wavelengths.   
Figure 3.19.  Comparison between experimental (black) and calculated (red) UV (top) and ECD (bottom) spectra.  The 
calculated (R)-enantiomer is opposite of the experimental spectrum, with a large difference in fits (Δ=0.8289) 
suggesting a confident assignment.  The calculated spectrum has been shifted -34 nm, and a band broadening of 0.3 
eV has been applied. 
 




Figure 3.21. Six conformers of the (R)-enantiomer of truncated deflectin-1a that contribute >5% to the Boltzmann 






Coordinates and electronic energies for B3LYP/6-31G** conformational minima 
contributing >5% to the in vacuo Boltzmann distribution. 
 
 
       Conformer 1: -1033.613962 hartrees        
z 
6 1.12532 -0.04345 -0.39212 
6 1.99275 0.732157 0.506105 
6 3.30798 0.164545 0.702653 
6 3.70807 -0.95125 0.058724 
8 2.8718 -1.61446 -0.80807 
6 1.61067 -1.16264 -0.98929 
6 -0.24074 0.436799 -0.53748 
6 -0.45225 1.9203 -0.3767 
6 0.276203 2.47925 0.879938 
6 1.57228 1.87365 1.13487 
6 5.0355 -1.62273 0.154105 
8 -0.18568 3.42614 1.49476 
6 -1.45471 -0.16625 -0.63897 
6 -2.49589 0.888061 -0.45779 
8 -1.86713 2.0917 -0.28838 
8 -3.69893 0.782672 -0.43922 
6 -1.75682 -1.61382 -0.78063 
8 -0.96298 -2.36216 -1.34426 
6 -3.0367 -2.1407 -0.16933 
6 -3.06518 -1.968 1.36533 
6 -1.88548 -2.64397 2.07088 
6 0.047576 2.71521 -1.59817 
1 4.91526 -2.65373 0.503621 
1 5.69066 -1.08748 0.843001 
1 5.51202 -1.66536 -0.83119 
1 -1.96232 -2.53676 3.1572 
1 -1.84539 -3.71359 1.8375 
1 -0.92928 -2.20641 1.76156 
1 -0.18359 3.77097 -1.44072 
1 -0.46423 2.36183 -2.49698 
1 1.12617 2.59644 -1.7238 
1 -3.10279 -3.19773 -0.44239 
1 -3.88139 -1.59557 -0.60229 
1 -4.00926 -2.38602 1.73215 
1 -3.09299 -0.90045 1.60707 
1 4.00284 0.655146 1.37472 
1 1.02743 -1.78942 -1.64834 
1 2.20866 2.37403 1.8575 
 
 




1.12455 -0.26641 0.307283 
6 
-
2.26771 0.221135 -0.47835 
6 
-
3.34533 -0.7326 -0.62018 
6 
-
3.31263 -1.94174 -0.02342 
8 
-
2.23687 -2.33275 0.738887 
6 
-
1.17513 -1.50542 0.861629 
6 0.02309 0.624155 0.393856 
6 
-
0.26797 2.1012 0.310862 
6 
-
1.23803 2.44194 -0.8567 
6 
-
2.28943 1.45998 -1.06108 
6 
-
4.35993 -3.00144 -0.06963 
8 
-
1.15626 3.51001 -1.44011 
6 1.37198 0.449204 0.391607 
6 1.99964 1.79257 0.218404 
8 1.00322 2.72868 0.145072 
8 3.16773 2.08818 0.142914 
6 2.14281 -0.81834 0.425308 
8 1.66299 -1.82714 0.93665 
6 3.53106 -0.82161 -0.18453 
6 4.14405 -2.21836 -0.30714 
6 3.46052 -3.08584 -1.36975 
6 
-
0.89721 2.64077 1.61047 
1 
-





5.20818 -2.68012 -0.67588 
1 
-
4.71146 -3.23342 0.941464 
1 3.94002 -4.06679 -1.44702 
1 2.40785 -3.24503 -1.12034 
1 3.51058 -2.61139 -2.35686 
1 -1.0324 3.71945 1.5056 
1 
-
0.22707 2.43922 2.4501 
1 
-
1.86575 2.17166 1.79764 
1 4.14471 -0.15612 0.43636 
1 3.49183 -0.31005 -1.15492 
1 4.08734 -2.71781 0.665863 
1 5.20723 -2.10655 -0.54866 
1 
-
4.21514 -0.46655 -1.20995 
1 
-
0.36813 -1.93743 1.43516 
1 
-
3.11123 1.75434 -1.70571 
 
       Conformer 3: -1033.613578 hartrees        
z 
6 -1.23669 0.367215 -0.25506 
6 -2.39903 -0.12519 0.498848 
6 -3.45192 0.849675 0.677926 
6 -3.38244 2.08379 0.13827 
8 -2.29045 2.48058 -0.59741 
6 -1.2499 1.63178 -0.7509 
6 -0.11296 -0.54982 -0.37714 
6 -0.44715 -2.02001 -0.36658 
6 -1.4339 -2.38875 0.778195 
6 -2.45933 -1.38886 1.02254 
6 -4.40172 3.16789 0.226283 
8 -1.38534 -3.48506 1.31077 
6 1.24071 -0.41422 -0.36279 
6 1.82764 -1.78285 -0.25038 
8 0.804028 -2.69148 -0.22508 
8 2.98556 -2.11847 -0.18343 
6 2.04843 0.831619 -0.33746 
8 1.59408 1.88107 -0.78567 
6 3.43612 0.767733 0.264145 
6 4.12596 2.12836 0.346454 
6 5.53042 2.02448 0.946302 
6 -1.08342 -2.47786 -1.69396 
1 -3.96898 4.05911 0.693254 
1 -5.26285 2.84194 0.811555 
1 -4.73918 3.45517 -0.77537 
1 6.01292 3.00558 0.997751 
1 5.49985 1.6137 1.96193 
1 6.17009 1.36781 0.346005 
1 -1.25056 -3.55592 -1.64194 
1 -0.40215 -2.25596 -2.5194 
1 -2.03663 -1.97206 -1.86332 
1 4.01855 0.049544 -0.32738 
1 3.36471 0.290609 1.25149 
1 3.50852 2.81195 0.940619 
1 4.17124 2.56697 -0.65634 
1 -4.33325 0.579987 1.24865 
1 -0.42639 2.06877 -1.29639 
1 -3.29392 -1.69019 1.64721 
 
 




1.16263 -0.38101 0.220523 
6 
-
2.40001 0.133099 -0.38523 
6 
-
3.44651 -0.85331 -0.53626 
6 
-
3.30464 -2.1192 -0.09307 
8 -2.1423 -2.53751 0.51102 
6 
-
1.10736 -1.67595 0.626863 
6 
-
0.04957 0.55392 0.301997 
6 
-
0.41246 2.01128 0.432348 
6 
-
1.51029 2.43529 -0.58532 
6 
-
2.53386 1.42861 -0.80765 
6 
-
4.30737 -3.21985 -0.16391 
8 
-
1.53384 3.56825 -1.03667 
6 1.29868 0.455493 0.146455 
6 1.84474 1.84502 0.081729 
8 0.80578 2.72429 0.224366 
147 
 
8 2.98285 2.21887 -0.06994 
6 2.11868 -0.76834 -0.04675 
8 1.72595 -1.85224 0.377492 
6 3.42359 -0.63768 -0.80651 
6 4.20384 -1.94904 -0.92925 
6 4.84226 -2.39582 0.390592 
6 
-
0.92807 2.35529 1.84364 
1 
-
3.90327 -4.06598 -0.72992 
1 
-
5.22487 -2.87623 -0.64395 
1 
-
4.54526 -3.58327 0.841596 
1 5.41245 -3.32099 0.258882 
1 5.52894 -1.63143 0.772205 
1 4.07651 -2.57643 1.14925 
1 
-
1.12083 3.42941 1.88756 
1 
-
0.16683 2.09296 2.58284 
1 -1.8505 1.81319 2.06358 
1 4.01663 0.149602 -0.32628 
1 3.17871 -0.22008 -1.79379 
1 4.98355 -1.81297 -1.68758 
1 3.53375 -2.73376 -1.29737 
1 
-
4.38175 -0.5671 -1.00381 
1 
-
0.22974 -2.12859 1.06416 
1 
-
3.42927 1.75158 -1.32867 
 
       Conformer 5: -1033.613417 hartrees        
z 
6 -1.28767 0.218168 -0.29924 
6 -2.21665 -0.5007 0.585253 
6 -3.45445 0.199085 0.84786 
6 -3.74166 1.38401 0.271162 
8 -2.8556 1.99399 -0.58535 
6 -1.65796 1.41507 -0.82441 
6 0.010014 -0.40554 -0.5129 
6 0.047735 -1.9102 -0.42909 
6 -0.70447 -2.44705 0.822674 
6 -1.91543 -1.71289 1.14633 
6 -4.98261 2.19305 0.436761 
8 -0.33731 -3.47014 1.37615 
6 1.28483 0.053474 -0.64059 
6 2.19597 -1.1267 -0.54633 
8 1.43292 -2.25264 -0.40061 
8 3.40297 -1.17042 -0.57187 
6 1.75903 1.45745 -0.75213 
8 1.01665 2.33155 -1.19275 
6 3.16063 1.78466 -0.28827 
6 3.34581 1.5836 1.23018 
6 4.76986 1.9244 1.67516 
6 -0.57977 -2.57506 -1.67001 
1 -4.7392 3.18535 0.831304 
1 -5.6774 1.69967 1.11806 
1 -5.47437 2.33802 -0.53116 
1 4.88825 1.7911 2.75506 
1 5.49623 1.2759 1.17413 
1 5.02313 2.96293 1.4345 
1 -0.4718 -3.6575 -1.57239 
1 -0.05535 -2.23779 -2.56775 
1 -1.63953 -2.32352 -1.75203 
1 3.35205 2.82513 -0.56546 
1 3.86638 1.13206 -0.81272 
1 3.12583 0.542541 1.48743 
1 2.62291 2.2093 1.76876 
1 -4.18405 -0.24573 1.51496 
1 -1.02206 2.00861 -1.46489 
1 -2.58722 -2.17362 1.86324 
 
       Conformer 6: -1033.613007 hartrees        
z 
6 -1.33004 -0.33625 0.191808 
6 -2.46505 0.40933 -0.37277 
6 -3.67628 -0.36659 -0.52076 
6 -3.75735 -1.64969 -0.11357 
8 -2.67727 -2.28908 0.448706 
6 -1.50175 -1.63261 0.561122 
6 -0.06485 0.378031 0.271432 
6 -0.15474 1.8741 0.43505 
6 -1.17503 2.515 -0.54881 
6 -2.36977 1.71762 -0.7651 
6 -4.94413 -2.5486 -0.1861 
8 -0.99925 3.64314 -0.97797 
6 1.24305 0.040367 0.096574 
6 2.0288 1.30911 0.044704 
148 
 
8 1.16892 2.35948 0.216565 
8 3.21456 1.47291 -0.11853 
6 1.83025 -1.30289 -0.13255 
8 1.2409 -2.31551 0.238784 
6 3.18478 -1.41488 -0.79951 
6 4.30321 -1.49201 0.263832 
6 5.68656 -1.61045 -0.37837 
6 -0.57534 2.27283 1.86396 
1 -4.71207 -3.43639 -0.78408 
1 -5.79421 -2.0308 -0.63283 
1 -5.22243 -2.89313 0.815677 
1 6.46885 -1.68168 0.384072 
1 5.75537 -2.49987 -1.01506 
1 5.90155 -0.73386 -0.99846 
1 -0.5682 3.36281 1.93305 
1 0.138091 1.85931 2.58141 
1 -1.57714 1.90262 2.09278 
1 3.37509 -0.5662 -1.46007 
1 3.1723 -2.33988 -1.38505 
1 4.10728 -2.35242 0.914763 
1 4.26382 -0.59047 0.882688 
1 -4.55345 0.097571 -0.95702 
1 -0.7104 -2.24947 0.96088 
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Chapter 4: One-pot synthesis of tricyclic azaphilones using a two enzyme 
sequence 
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Summary 
 Polyketide synthases and their related tailoring enzymes can construct and 
decorate natural product scaffolds with ease and efficiency. Acyltransferases (ATs) are a 
common enzyme domain from pathways containing PKSs that can exist as part of the 
PKS or function independently post-PKS, such as in the azaphilone natural product class. 
Despite their abundance and critical role in biosynthesis, there are a limited number of 
reports describing the use of ATs in biocatalysis and natural product total synthesis. To 
streamline the synthesis of tricyclic azaphilone natural products and their analogs, we 
describe the use of the AT MrPigD in a one-pot enzymatic sequence to provide access 
to these scaffolds from resorcinol substrates. Combining this enzyme with the FAD-
dependent monooxygenase (FDMO) AzaH and a pantetheine-based acyl group donor 
allowed for the conversion of several orcinaldehyde substrates directly to the 
corresponding tricyclic azaphilone in a single reaction vessel, eliminating the need to 
isolate the dearomatized intermediate. This approach was used to provide preparative-
scale quantities of three azaphilone tricycles, including the natural product rubropunctatin 
(4.10). NMR characterization of these compounds indicated that the acylated 
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intermediate can undergo a subsequent cyclization reaction with selectivity that is 
complementary to those reported previously, providing access to linear tricyclic scaffolds 
with unprecedented selectivity. 
  
4.1 Introduction 
 Biosynthetic pathways consist of enzymatic machinery responsible for 
constructing complex natural products with valuable biological activity.1-5 Metabolites from 
these pathways can exhibit impressive structural diversity in addition to interesting 
pharmacological properties, ranging from enormous marine toxins,6 large macrocyclic 
antibiotics,7 and functionalized bicyclic protein inhibitors.4 The synthetic chemistry 
community now recognizes the operational efficiency of enzymes like the ones 
responsible for these biosyntheses; the field as a whole continues to embrace the use of 
enzymes in total synthesis.8-18 With recent advances in biocatalysis and molecular biology 
lowering the barrier for their use by making it easier and less expensive to obtain them,10-
13, 15, 19-24 there is incredible potential to further exploit catalytic proteins like those from 
natural product biosynthetic pathways for synthetic endeavors. 
Azaphilones are one class of natural products biosynthesized by fungi through 
polyketide synthase (PKS) pathways.25-27 This large natural product class exhibits 
impressive structural diversity, made possible by the seamless cooperation of the PKS 
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architecture and downstream tailoring enzymes.27 In particular, many azaphilones with 
potential medicinal properties have been identified that bear additional rings such as 
butenolides or lactones appended to the basic pyranoquinone core (Figure 4.1A).27-31 
Typically, these ring systems are constructed following introduction of the acyl group by 
acyltransferases (ATs) operating in conjunction with other substrates and domains from 
Figure 4.1. A) Azaphilone natural products containing additional ring systems. B) Native reactions of ATs PigD 
and CazE. C) Biocatalytic retrosynthesis of acylated azaphilones. 
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the pathway.25, 32 Such as in the biosynthesis of azaphilone natural products 
rubropunctatin (4.10) and chaetoviridin A (4.14), the ATs MrPigD25 (PigD) and CazE32 
catalyze the transfer of an ACP-bound fatty acyl chain to the C7 hydroxyl on the 
azaphilone bicycle (Figure 4.1B). Following acylation, the linear intermediate is reported 
to undergo a spontaneous Knoevenagel condensation, with the newly introduced acyl 
chain forming a C–C bond with either the C6 or C8 carbonyl group carbon, resulting in a 
linear or angular tricycle, respectively.25, 32-35 The pharmacology of these highly 
functionalized azaphilones remains poorly understood,29, 30, 36, 37 motivating the 
development of better synthetic techniques to diversify these scaffolds for examination in 
biological assays and structure activity relationship (SAR) studies. 
 ATs are commonly found as part of biosynthetic pathways and play a vital role in 
adding complexity to natural products cores constructed by PKSs.38-40 Despite being 
essential in the biosynthesis of many metabolites,41 relatively few recent reports describe 
the use of ATs for in vitro biocatalysis. Schmidt and coworkers engineered a hetero-
trimeric bacterial AT construct, called PpATaseCH, as a biocatalyst to efficiently affect 
two types of acylation reactions on several resorcinol substrates.42 Furthermore, this 
enzyme accepts a variety of acyl donor substrates to affect the transformation, 
demonstrating impressive substrate promiscuity and eliminating the need to rely on a 
CoA-activated fatty acid substrates to load the AT.42 Xie and coworkers also reported the 
use of LovD, an AT from the lovastatin biosynthetic pathway, as a biocatalyst.39 This 
enzyme is capable of generating a diverse array of lovastatin analogs in vitro by 
regioselective acylation of the C8 hydroxyl group on monacolin J and 6-hydroxyl-6-
desme-thylmonacolin J.39 Wild type LovD exhibits impressive promiscuity towards the 
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acyl-donor reagent, accepting a total of 22 different thioester substrates and thus 
removing the need for an  ACP for productive catalysis.39 
 Previously, our group35 and others33, 34 have reported the total synthesis of tricyclic 
azaphilones natural products that possess a third ring most likely installed from the action 
of ATs. However, these syntheses require forcing reaction conditions and isolation of 
reactive dearomatized intermediates, in addition to producing mixtures of linear (such as 
4.1) and angular (see 4.4) tricyclic products depending on the particular azaphilone 
substrate used.33-35 For example, in their synthesis of analogs of the linear tricyclic 
azaphilone natural product epicocconone, Franck and coworkers report some degree of 
regioselectivity in favor of linear tricycle production by leveraging steric effects from bulky 
acyl groups.34 Despite this important contribution to the field in synthesizing the first 
synthesis of a linear tricyclic azaphilone, the drawback to this methodology is that it is 
limited to specific bulky acyl groups to achieve the linear selectivity. It is theorized that the 
increased steric bulk afforded by these larger substituents is responsible for biasing the 
condensation regioselectivity towards the linear scaffold.34 By contrast, Nature is able to 
achieve the condensation regioselectivity affording the linear tricyclic scaffold through 
manipulations of the azaphilone core π-system.25 Such is the case for the natural product 
rubropunctatin (4.10). Following acylation by PigD, the substrate is reported to undergo 
enzymatic reduction, truncating the conjugated π system of the bicyclic intermediate. This 
reportedly changes the activity of the two ketones such that the C6 carbonyl is more now 
electrophilic than the C8 carbonyl, allowing for cyclization in the linear direction. The initial 
π-system is then restored by a downstream oxidoreductase.25  
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We envisioned an improved synthesis could proceed through a one-pot, two-enzyme 
sequence to afford linear tricyclic azaphilones. Given that enzymes can operate 
synergistically in Nature,5 we sought to identify an AT to provide efficient access to 
acylated azaphilones in a biomimetic approach (Figure 4.1C). To access analogs of 
acylated azaphilone bicycles (4.15), we investigated the AT PigD from a Monascus ruber 
biosynthetic pathway25 for its ability to acylate azaphilone intermediates (i.e. 4.17). 
Inspired by the efficiency of biocatalysts like LovD operating without the putative ACP,39 
we sought to substitute the canonical Monascus ACP from this pathway with a synthetic 
thioester 4.16 as shown previously,25 eliminating the need for a protein-bound acyl 
substrate in our system. To further streamline the synthesis of azaphilone tricycles, we 
proposed constructing the dearomatized acyl-acceptor substrates (4.17) in situ through 
the dearomatization of orcinaldehyde starting materials (such as 4.18) by AzaH35, 43 
(Figure 4.1C).  
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4.2 Selecting and Optimizing Acyltransferase PigD 
 Studies of azaphilone 
biosynthesis have revealed many 
pathways containing ATs performing 
acylations on dearomatized 
compounds.1 After a careful search of 
relevant literature, we identified PigD25 
and CazE32 as potential enzymes for 
investigation. Performing similar roles in 
the production of tricyclic azaphilones, 
these enzymes were chosen due to their 
reported promiscuity (catalyzing the 
transfer of several different acyl chains), 
the established precedent for their 
production in E. coli, and their ability to perform their reported functions in vitro.25, 32 Chen 
and coworkers also report that PigD recognizes a pantetheine-based thioester (4.20, 
Figure 4.3A) as the acyl donor in place of the native ACP, further reinforcing our interest 
in this enzyme.25 In addition, to provide the best opportunity of identifying an AT with 
suitable activity and substrate promiscuity, a sequence similarity network (SSN)44-46 with 
an alignment score of 90 was constructed using the pigD gene as the input sequence 
(Figure 4.2). From this SSN, 12 putative AT sequences with varying degrees of 
relatedness to PigD were identified and ten were selected for investigation. These 
particular sequences were chosen through a subsequent genome neighborhood analysis 
Figure 4.2. SSN of transferase proteins related to PigD 
created using web tools originating from the Enzyme 
Function Initiative. The green diamond represents the 
pigD sequence and the blue circles represent tran1-12 
sequences. This SSN was generated with an alignment 
score of 90. 
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indicating that, similarly to PigD and CazE, they also neighbor an FDMO in their 
respective pathways,.44, 45  
 To test the hypothesis that an AT could be used to functionalize dearomatized 
intermediates in vitro, the synthetic genes for pigD, cazE, and the ten uncharacterized 
ATs were transformed into E. coli BL21(DE3) cells and the proteins were expressed 
following reported conditions.25, 32 Enantioenriched azaphilone 4.19 was prepared as 
reported previously43 and added to clarified cell lysates containing the ATs (see 
Experimental) under the conditions reported in Figure 4.3A. No product was detected in 
the samples containing CazE and the ten uncharacterized ATs, most likely due to low 
levels of expression (Figure 4.6). The reaction containing PigD lysate however adopted 
a distinct red color following incubation for 30 min at 30 °C. Analysis of the reaction by 
LC-MS revealed a mass corresponding to successful acylation. Analysis of this reaction 
by UPLC with monitoring at 450 nm also suggested formation of a tricyclic azaphilone: a 
Figure 4.3. A) Reaction scheme of PigD clarified lysate with native azaphilone bicycle. B) Buffer pH and 
concentration optimization data. Product was detected at 450 nm and normalized to the pentamethyl benzene 
internal standard (1 mM final concentration) at 270 nm. All reactions were performed in duplicate. 
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UV signature matching that reported by Chen and coworkers in PigD in vitro reactions 
was detected (see Experimental). Following this initial success, a brief optimization of 
reaction conditions was performed (Figure 4.3B). These experiments indicate that PigD 
is tolerant of varied conditions, but optimal production of 4.21 appears to occur in 25 mM 
Tris, KPi, or HEPES buffer pH 8.4.  
 Upon reaction quenching, we observed significant red coloration of the insoluble 
material following centrifugation, suggesting the product molecule may have precipitated 
alongside the protein through adherence to the biological material or through a covalent 
attachment to the protein itself. As these tricyclic azaphilones are known to readily 
condense onto amino acids through formation of a Schiff base,25, 30, 34, 47 we suspected 
any free amines from remaining endogenous E. coli proteins in the cell lysate could be 
contributing to precipitation of 4.21. Therefore, purified PigD was obtained using a 
protocol modified from a previous report25 (see Experimental) and used in lieu of clarified 
cell lysate for the remainder of this study. 
 
4.3 Substrate Screen and Preparative-Scale Reactions with PigD 
 With optimized conditions and purified PigD in hand, we then investigated the 
ability of this enzyme to functionalize dearomatized intermediates formed in situ using 
AzaH (Figure 4.4A). First, a focused panel of orcinaldehyde substrates examined 
previously was dearomatized using AzaH under standard conditions.35, 43 After confirming 
successful dearomatization, the pH of the reactions was adjusted from 8 to 8.4, 1 
equivalent of thioester 4.20 was added, and 20 μM PigD was added to the mixture. 
Gratifyingly, a significant color change was observed with the five substrates depicted in 
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Figure 4.4B under these conditions. UPLC-DAD and LC-MS analysis of these reactions 
confirmed the presence of both the acylated and tricyclic material, whereas the AzaH only 
negative controls did not contain masses corresponding to the desired tricyclic products 
(see Experimental). At 450 nm, we observed a peak in the UPLC trace from four of the 
five reactions with a UV signature matching that observed for the product following 
acylation of 4.19 (see Experimental). This peak was not present in the AzaH only controls, 
supporting the hypothesis that PigD is indeed responsible for mediating this 
transformation (see Experimental). Additionally, both the [M+H]+ and [M+H+H2O]+ 
product masses can be seen for reactions containing PigD compared to spectra collected 
for the AzaH only samples (see Experimental).  
 Despite an obvious color change (C, Figure 4.4B), the UV signature of the 
expected peak from this sample did not resemble that of 4.25A. Instead, this spectrum 
Before After
Figure 4.4. A) Reaction scheme of the one-pot transformation of orcinaldehydes by AzaH and PigD. B) Substrate 
screen of PigD in a well plate. C) Preparative scale one-pot synthesis of rubropunctatin (4.10). 
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matches those publishIed for the natural products rubropunctatin and monascorubrin (see 
Experimental).25 This result was unexpected, as it indicated that the acylated intermediate 
had undergone a spontaneous Knoevenagel condensation onto the C6 carbonyl of the 
azaphilone core to furnish a linear tricycle. This cyclization selectivty conflicts with that 
observed from our previous experiments with this particular substrate in our total 
synthesis of the enantiomers of the angular tricyclic azaphilone trichoflectin (3.1, Chapter 
3),35 and it contradicts the report describing how the biosynthetic pathway of 
rubropunctatin (4.10) and monascorubrin (4.1) achieves this selectivity.25 
 To confirm that enzymatic acylation led to formation of the linear tricycle to produce 
the natural product rubropunctatin (4.10), a prepartive-scale reaction was performed to 
provide material for NMR studies (Figure 4.4C). 2 mg of the enone orcinaldehyde (4.22C, 
Figure 4.4C) was first dearomatized with AzaH, followed by a pH adjustment and addition 
of 4.20 and PigD to the reaction mixture. After one hour, the reaction was diluted with 
saturated Na2SO4. The crude material was then extracted from the aqueous phase by 
liquid-liquid extraction with 9:1 ethyl acetate:n-butanol before it was concentrated and 
subjected to separation conditions by preperative HPLC (see Experimental). The 1H and 
13C NMR spectra from the purified material, isolated as an amorphous orange solid, 
matches with those reported for rubropunctatin and monascorubrin, indicating the 
succesful total synthesis of 4.10.48 
 After confirming the condensation regioselectivity of this transformation, we 
investigated whether this observation held true for other substrates. To access material 
for additional NMR studies, we performed a preparative scale reaction with the reported 
native substrate of PigD (4.22A, Figure 4.4B) and an orcinaldehyde containing a propyl 
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ketone (4.22B, Figure 4.4B), under the same conditions. Following separation and 
purification, comparison of the resulting 1H spectra to that of 4.10 shows an excellent 
correlation, particularly those of the signals afforded by the vinylogous protons appended 
to C1, C4, and C5 on the azaphilone pyranoquinone core (see Experimental). This 
strongly suports the selective formation of linear tricycles under these conditions and 
suggests that the preferance for the C6 carbonyl during the condensation reaction is not 
isolated to a single substrate, as the characteristic vinylogous proton signals are 
signifiacntly shifted in NMR spectra published for similar angular tricycles.33-35 
 The mechanism for this observed cyclization selectivty is currently not understood; 
however we have developed two working hypotheses. The first being that the preferance 
for condensation onto the C6 carbonyl is controlled directly by PigD through an unknown 
substrate-enzyme interaction. Alternativley, we suspect that the true substrate for PigD is 
not the “closed” pyranoquinone (4.24, Figure 4.4A) formed from a dehydration event 
following dearomatization of the aromatic substrate by an FDMO.1, 25, 43 Instead, we 
speculate that PigD perfers the “open” dienol form of the dearomatized intermediate 
(4.23, Figure 4.5) as its substrate. This theory is supported by the observation that the 
dienol is the direct product of FDMOs like 
AzaH and that the dearomatized species 
are persistent in solution.43 We have also 
observed only trace product formation 
when PigD is used to acylate the isolated 
bicycle directly as opposed to when this 
dearomatized material is generated in Figure 4.5. Mechanistic hypothesis for the observed 
condensation regioselectivity afforded through acylation 
of dearomatized substrates by PigD.  
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situ using AzaH. We thus hypothesize that direct acylation of this dieneol form could 
confer the observed selectivity in a substrate-dependent manner (Figure 4.4).34  
 
4.4 Conclusion and Future Directions 
 In this Chapter, we described the total synthesis of an azaphilone natural product 
and several analogs through a one-pot, two-enzyme sequence. Two ATs from azaphilone 
biosynthetic pathways were initially investigated for their ability to catalyze an acyl transfer 
through clarified cell lysate reactions with an azaphilone bicycle substrate. Of these two 
enzymes, PigD displayed signifcant acylation activity, determined by UPLC-DAD and LC-
MS. After moving to a purified enzyme platform, we demonstrated the ability of PigD to 
not only perform an acylation reaction on multiple dearomatized substrates generated in 
situ, but also that these reaction conditions afford linear tricycles exclusively. This 
unprecedented cyclization selectivity provided a means to complete the first reported total 
synthesis of the natural product rubropunctatin. Preperative-scale reactions with two other 
substrates under these conditions afforded synthetic analogs of the natural product, as 
well. NMR analysis of these analogs confirms they are also linear tricycles, suggesting 
that this unexpected cyclization selectivity holds true for multiple substrates. 
 Moving forward, we will continue exploring the substrate scope of PigD with other 
thioester substrates and dearomatized intermediates in the system described above 
towards constructing a diverse library of linear tricyclic azaphilones. We intend to also 
further probe the source of the observed cyclization regioselectivity through generation of 
the uncylized, acylated intermediate (see 4.15) synthesized through conventional 
chemical means. Due to the ease in which the reactions can be conducted in a 96 well 
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plates, we also have plans  to collaborate with the Sexton Lab at the University of 
Michigan to screen compounds synthesized with this methodology for biological activity 
in their high-throughput and high-content assays in search of novel pharmacophores.  
 
4.5 Experimental 
I. Substrate synthesis 
All reagents were used as received unless otherwise noted. Reactions were carried out 
under a nitrogen atmosphere using standard Schlenck techniques unless otherwise 
noted. Solvents were degassed and dried over aluminum columns on an MBraun solvent 
system (Innovative Technology, inc., Model PS-00-3). Reactions were monitored by thin 
layer chromatography using Millipore 60 F254 precoated silica TLC plates (0.25 mm) that 
were visualized using UV, p-anisaldehyde, CAM, DNP, or bromocresol stain. Flash 
column chromatography was performed using Machery-Nagel 60 μm (230-400 mesh) 
silica gel. All compounds purified by column chromatography were sufficiently pure for 
use in further experiments unless otherwise indicated. 1H and 13C NMR spectra were 
obtained in CDCl3 at rt (25 °C), unless otherwise noted, on Varian 400 MHz or Varian 600 
MHz spectrometers. Chemical shifts of 1H NMR spectra were recorded in parts per million 
(ppm) on the δ scale. High resolution electrospray mass spectra were obtained on an 







Prepared as previously by Chen and coworkers.25 1H NMR (600 MHz, CDCl3) δ 7.52 – 
7.47 (m, 1H), 6.95 (dt, J = 11.0, 5.7 Hz, 1H), 3.95 (s, 1H), 3.67 (s, 2H), 3.54 – 3.32 (m, 
7H), 3.07 – 2.98 (m, 2H), 2.49 (t, J = 7.4 Hz, 2H), 2.40 (t, J = 6.2 Hz, 2H), 2.12 (t, J = 7.7 
Hz, 1H), 1.54 (p, J = 7.4 Hz, 2H), 1.29 – 1.21 (m, 4H), 0.93 (d, J = 2.9 Hz, 3H), 0.87 (s, 




Prepared as previously reported by Baker Dockrey et al.43 (see Chapter 3 for spectrum) 
  
(E)-2,4-Dihydroxy-3-methyl-6-(2-oxopent-3-en-1-yl)benzaldehyde (3.4) 
Prepared as previously by Pyser et al.35 (see Chapter 3 for spectrum) 
 
2,4-Dihydroxy-3-methyl-6-(2-oxopentyl)benzaldehyde (3.S9) 





Prepared as previously reported by Baker Dockrey et al.43 (see Chapter 3 for spectrum) 
 
2,4-dihydroxy-6-(3-methoxy-2-oxopropyl)-3-methylbenzaldehyde (3.S3) 
Prepared as previously by Pyser et al.35 (see Chapter 3 for spectrum) 
 
7-hydroxy-7-methyl-3-propyl-6H-isochromene-6,8(7H)-dione (4.24A) 
Prepared as previously reported by Baker Dockrey et al.2 
 
II. Plasmids and Proteins 
Plasmids: The plasmid encoding pigD (AGI63864.1),25 cazE (XM_001225292),32 tran1 
(from Stachybotrys chartarum, strain CBS 109288 / IBT 7711, A0A084B9Z3), tran2 (from 
Pseudogymnoascus sp. VKM F-4513, A0A094B1C4), tran3 (from Pseudogymnoascus 
sp. VKM F-103, A0A094EQW5),  tran4 (from Pseudogymnoascus sp. VKM F-4520,  
A0A094J5P9), tran5 (from Exophiala spinifera, A0A0D1YCS0), tran6 (from Aspergillus 
parasiticus, strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1, A0A0F0IK60), tran7 
(from unknown organism, A0A0F8UU93), tran8 (from Aspergillus rambellii, 








rabiei, A0A163CB57), tran11 (from Valsa mali var. pyri., A0A194UPD1), and tran12 (from 
Valsa mali., A0A194VYW6) were synthesized by Twist Biosciences and cloned into a 
pET-28a(+) vector. 
















































































































































































































































































































































































































































































































































































Overexpression of AT enzymes and preparation of clarified cell lysate: Plasmid 
containing the sequences of interest were used to transform chemically competent E. coli 
BL21(DE3) cells using standard heat-shock protocols. Overexpression of the proteins 
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was achieved in 1 mL of Luria Broth (LB) in 1.5 mL plastic tubes. 1 mL portions of media 
were inoculated with a single colony from an agar plate, along with 50 g/mL kanamycin 
(Gold Biotechnology). Cultures were grown at 37 C and 200 rpm until the optical density 
at 600 nm reached 0.8 (approx. 3.5 h). The cultures were then cooled to 16 C for 30 min 
and expression was induced with 0.1 mM isopropyl--D-1-thiogalactopyranoside (IPTG, 
Gold Biotechnology). Expression continued at 16 C overnight (approx. 18 h) at 200 rpm. 
Cultures were then pelleted by centrifugation at 17,000 xg for 10 min and the supernatant 
was removed. Cell pellets were resuspended in 50 mM KPi buffer pH 8.0 at a 
Figure 4.6. Induced and uninduced transferase 
proteins.  Approximately 7.5 µL each protein clarified 
lysate was loaded onto a 12.5% SDS-PAGE gel.  The 
gel was stained with Quick Coomassie stain 
(Anatrace) and visualized with the Azure Gel Imaging 
System. 1: Tran1 induced 2: Tran1 uninduced 3: 
Tran2 induced 4: Tran2 uninduced 5: Tran3 induced 
6: Tran3 uninduced 7: Tran4 induced 8: Tran4 
uninduced 9: Tran5 induced 10: Tran5 uninduced 11: 
Tran6 induced 12: Tran6 uninduced 13: Tran7 
induced 14: Tran7 uninduced 15: Tran8 induced 16: 
Tran8 uninduced 17: Tran9 induced 18: Tran9 
uninduced 19: Tran10 induced 20: Tran10 uninduced 
21: CazE induced 22: CazE uninduced  
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concentration of 50 mg of cell pellet/mL. The cell suspensions were then lysed by 
sonication on ice, 10 sec on 20 sec off x3. Insoluble material was pelleted by 
centrifugation at 17,000 xg for 10 min and the clarified supernatant was used directly for 
biocatalytic reactions. 
Large-scale PigD overexpression and purification: Plasmid containing the pigD 
sequence was used to transform chemically competent E. coli BL21(DE3) cells using 
standard heat-shock protocols. Overexpression of the protein was achieved in 1 L of 
Terrific Broth (TB) in 2.8 L flasks. 1 L portions of media were inoculated with 10 mL 
overnight culture prepared from a single colony in Luria Broth (LB) and 50 g/mL 
kanamycin (Gold Biotechnology).  Cultures were grown at 37 C and 200 rpm until the 
optical density at 600 nm reached 0.8 (approx. 3.5 h). The cultures were then cooled to 
16 C for 30 min and expression was induced with 0.1 mM isopropyl--D-1-
thiogalactopyranoside (IPTG, Gold Biotechnology). Expression continued at 16 C 
overnight (approx. 18 h) at 200 rpm. The typical yield for 1 L culture was ~17 g cell pellet. 
 
PigD purification procedure: Approximately 200 g of cell pellet was resuspended in 600 
mL of lysis buffer containing 50 mM Tris HCl pH 7.5. 1 mg/mL lysozyme was added to 
the resuspended cells that were then incubated on a rocker at 4 C for 30 min. Cells were 
lysed by first sonicating the mixture on ice, 10 sec on 20 sec off for a total of 3 min on. 
The total cell lysate was then passed through an Avestin pressure homogenizer at 15000 
psi. The total lysate was centrifuged at 40,000 x g for 30 min, then the supernatant was 
mixed with roughly 5 mL of concentrated Ni-NTA resin and incubated on a rocker at 4 C 
for 1h. The impregnated resin was removed from the mixture by a gravity flow column 
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and rinsed with 30 mL of wash buffer containing 50 mM Tris HCl pH 7.5 and 5 mM 
imidazole. The protein was eluted from the resin with 10 mL of elution buffer containing 
50 mM Tris HCl pH 7.5 and 250 mM imidazole. The eluted protein was passed through a 
desalting PD10 column and eluted in a storage buffer containing 25 mM Tris HCl pH 8.4 
and 10% glycerol. The eluted protein was then concentrated to 1.7 mM (determined by 
Pierce assay) using a 30,000 NMWL Amicon Ultra-15 centrifugal filter. Average yields: 
14 mg from 1 L PigD. The molecular weight of PigD including the 6xHis-tag was estimated 
by the ProtParam tool on the Expasy server to be 50.2 kDa. This molecular weight is 
consistent with the mass of the protein band observed by SDS-PAGE analysis (Figure 
4.6). The purified protein was aliquoted into 0.6 mL tubes and frozen in liquid nitrogen 







Figure 4.7. Purified AzaH and PigD.  Approximately 
2 µL of 20 µM each protein was loaded onto a 12.5% 
SDS-PAGE gel.  The gel was stained with Quick 
Coomassie stain (Anatrace) and visualized with the 
Azure Gel Imaging System. The relative apparent 
masses are consistent with the predicted estimates. 
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III. Biocatalytic reactions 
 
Stock solutions: Stock solutions of each substrate (50 mM) were prepared by dissolving 
the substrate in DMSO (analytical grade) and stored at -20 °C. Stock solutions of NADP+ 
(100 mM) and glucose-6-phosphate (G6P, 500mM) were stored at -20 °C. Aliquots of 
each enzyme and glucose-6-phosphate dehydrogenase (G6PDH, 100 U/mL) were stored 
at -80 °C.  
 
Analytical-scale reactions with clarified cell lysate: Each reaction contained 2.5 mM 
of bicycle 4.19 substrate (5 uL of a 50 mM stock solution in DMSO), 2.5 mM thioester 
4.20 (5 uL of a 50 mM stock solution in DMSO), in enzyme clarified lysate (90 uL, 
prepared as described above).  The reactions were quenched with 200 μL of MeOH and 
the precipitated biomolecules were pelleted by centrifugation (16,000 x g, 12 min). The 
supernatant was then analyzed by UPLC-DAD and LC-MS. 
 
Analytical-scale reactions with purified enzyme: Each reaction contained 2.5 mM of 
the orcinaldehyde substrate (5 uL of a 50 mM stock solution in DMSO), 5 mM G6P (1 μL, 
500 mM), 1 mM NADP+ (1 μL, 100 mM), 1 U/mL G6P-DH (1 μL, 100 U/mL), 5 μM AzaH 
(3.3 μL of a 150 μM stock solution), and 85 μL of a 50 mM potassium phosphate buffer, 
pH 8.0. The dearomatization reaction was carried out at 30 °C for 1 h. Following this, the 
pH of the reactions were adjusted to ~8.4 using 1 μL 200 mM NaOH. 2.5 mM thioester 
4.20 (2.5 μL of a 100 mM stock solution in DMSO) and 20 μM PigD (1.2 μL of a 1.7 mM 
stock solution) were then added, and the second reaction was carried out at 30 °C for 1 
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h. The reactions were quenched with 200 μL of MeOH and the precipitated biomolecules 
were pelleted by centrifugation (16,000 x g, 12 min). The supernatant was then analyzed 
by UPLC-DAD and LC-MS. 
 
General procedure for preparative scale in vitro reactions: 
2.5 mM orcinaldehyde substrate (171 uL of a 50 mM stock solution in DMSO), 5 mM G6P 
(34 μL, 500 mM), 1 mM NADP+ (34 μL, 100 mM), 1 U/mL G6P-DH (34 μL, 100 U/mL), 5 
μM AzaH (113 μL of a 150 μM stock solution) was added to 2.8 mL of 50 mM potassium 
phosphate buffer, pH 8.0. The reaction was placed in an incubator at 30 °C with 85 rpm 
shaking. After 1 h, the pH of the mixture was adjusted to ~8.4 with 6.8 μL 1 M NaOH. 2.5 
mM thioester 4.20 (85 μL of a 100 mM stock solution in DMSO) and 20 μM PigD (40 μL 
of a 1.7 mM stock solution) were then added, and the reaction was returned to the 30 °C 
for 1 h without shaking. The reaction was then diluted with a saturated sodium sulfate 
solution (~10x reaction volume) and extracted 3 times with ~10 mL 9:1 EtOAc:n-BuOH. 
The combined organic layers were washed with ~30 mL of brine, then dried with sodium 
sulfate. The sodium sulfate and precipitated biomolecules were removed through gravity 
filtration and the flow-through was passed through a 0.22 μm filter before the solvent was 
removed using a rotary evaporator. The resulting crude oil was dissolved in ~500 μL of 
HPLC grade MeOH and subjected to purification by preparative HPLC using a 
Phenomenex Kinetex 5 µm C18, 150 x 21.2 mm column under the following conditions: 
mobile phase A = deionized water and B = acetonitrile; method = 5% to 20% B over 4 
min, 20% to 50% B over 9 min, 50% to 100% B over 2 min, 100% B for 3 min; flow rate, 
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10 mL/min. Fractions containing the purified compound were pooled and the solvent was 




Following preparation by the general method described above, the title compound was 
isolated as an orange, amorphous solid (11% yield by NMR over two steps). 1H NMR 
(600 MHz, CDCl3) δ 7.86 (s, 1H), 6.89 (s, 1H), 6.56-6.62 (m, 1H), 6.14 (s, 1H), 6.03-6.06 
(d, J = 7 Hz, 1H), 2.89-2.99 (m, 2H), 1.95-1.96 (d, J = 7.0 Hz, 3H), 1.71 (s, 3H), 1.59-1.64 
(m, 4H), 1.31-1.33 (m, 2H), 0.88-0.89 (t, J = 5.0 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
197.6, 191.0, 171.8, 169.4, 156.54, 152.9, 141.7, 136.5, 122.5, 116.5, 113.4, 109.7, 
104.3, 85.9, 41.8, 31.6, 28.5, 23.6, 18.9, 14.1. HR-ESI-MS: m/z calculated for C21H23O5 
[M+H]+: 355.1540, found: 355.1546. All spectral data is consistent with available 







Following preparation by the general method described above, the resulting red oil was 
warmed to 40 °C under vacuum overnight (~14 h) to give the pure title compound as a 
brown oil (20% yield by NMR over two steps). 1H NMR (600 MHz, CDCl3) δ 7.85 (s, 1H), 
6.84 (s, 1H), 6.26 (s, 1H), 2.89-2.98 (m, 2H), 2.55-2.57 (m, 2H), 1.71 (s, 3H), 1.60-1.62 
(m, 4H), 1.32-1.33 (m, 2H), 0.87-0.90 (t, J = 6.7 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
197.4, 190.9, 171.9, 169.1, 160.3, 153.1, 140.9, 116.7, 113.7, 111.6, 111.6, 103.5, 85.90 
65.5, 65.4, 42.7, 42.6, 41.6, 31.38, 3.1, 23.7, 23.4, 22.5, 14.0. HR-ESI-MS: m/z calculated 





Following preparation by the general method described above, the title compound was 
isolated as an orange, amorphous solid (20% yield by NMR over two steps). 1H NMR 
(600 MHz, CDCl3) δ 7.85 (s, 1H), 6.82 (s, 1H), 6.15 (s, 1H), 2.89-2.98 (m, 2H), 2.40-2.43 
(t, J = 7.5 Hz, 2H), 1.71 (s, 3H), 1.65-1.69 (m, 4H), 1.31-1.33 (m, 4H), 0.99-1.01 (t, J = 
7.4, 3H), 0.88-0.90 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 197.6, 191.2, 172.3, 
169.4, 163.6, 153.5, 141.7, 116.8, 113.4, 109.9, 103.2, 86.0, 77.4, 77.2, 77.0, 41.8, 35.3, 
31.53, 28.4, 23.6, 22.7, 20.10, 14.1, 13.6. HR-ESI-MS: m/z calculated for C21H25O6 




IV. UPLC-DAD and LC-MS Traces 
Figure 4.8. One-pot enzymatic transformation of 4.19 by AzaH and PigD. PDA and LC-
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Figure 4.9. One-pot enzymatic transformation of 4.22B by AzaH and PigD. PDA and LC-
MS traces of enzymatic reaction and control reaction. 
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Figure 4.10. One-pot enzymatic transformation of 4.22C by AzaH and PigD. PDA and 
LC-MS traces of enzymatic reaction and control reaction. 
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Figure 4.11. One-pot enzymatic transformation of 4.22D by AzaH and PigD. PDA and 
LC-MS traces of enzymatic reaction and control reaction. 
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Figure 4.12. One-pot enzymatic transformation of 4.22E by AzaH and PigD. PDA and 
LC-MS traces of enzymatic reaction and control reaction. 
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Chapter 5: Conclusion and Future Directions 
 
Advances in molecular biology and biochemistry within the last few decades have 
provided organic chemists with access to synthetically useful enzymes from myriad 
biosynthetic pathways.1-18 Despite this, there is still a great deal to discover in the field of 
biocatalysis, requiring constant investigation of new enzymes and the reactions they 
catalyze. The body of work in this thesis seeks to provide access to molecular scaffolds 
with greater efficiency than attainable with analogous human-made methods using 
chemoenzymatic and multi-enzyme transformations. This Chapter summarizes the 
results of the preceding three chapters describing the identification and characterization 
of several known and unknown FDMOs, their application in the total synthesis of  
azaphilone natural products, and their combination with an AT enzyme to affect a one-
pot sequence towards analogs of tricyclic azaphilones.  
 
5.1 Conclusions 
Specifically, we investigated enzymes from PKS pathways, beginning with a study 
on FDMOs performing dearomatization reactions. Dr. Attabey Rodríguez Benítez applied 
a state of the art bioinformatic analysis, called an SSN, to search and organize the 
enormous quantity of sequence data available online from the FDMO Pfam. Using this 
tool, she identified seven previously uncharacterized FDMOs with potential for synthetic 
utility. Together, Dr. Rodríguez Benítez, Dr. Summer Baker Dockrey, and I investigated 
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the stereo- and regioselectivity of these enzymes in a model hydroxylative 
dearomaitzation reaction. Ultimately, we demonstrated that the SSN is a useful tool in 
predicting the regioselectivity of these enzymes, but discovered that the stereoselectivity 
of this transformation is more intricately controlled than can be predicted with the SSN. 
Follow up work by Dr. Rodríguez Benítez supports our findings from this initial study.19 
Following identification of the biocatalysts AzaH and AfoD, Dr. Baker Dockrey and 
I applied them to the chemoenzymatic total synthesis of three azaphilone natural 
products: trichoflectin, deflectin-1a, and lunatoic acid A. Careful analysis of the 
enantioenriched natural products from this study, in addition to calculated CD spectra and 
an X-ray crystal structure provided by Dr. Leo Joyce and Dr. Ren Wiscons, respectively, 
supports the need for structural revision of trichoflectin and deflectin-1a. These findings 
corrected an error in the azaphilone literature surrounding the original absolute 
configuration assignment of several azaphilone natural products.20 Total synthesis and 
characterization of lunatoic acid A confirms its original absolute configuration was 
assigned correctly. 
Finally, with a robust platform for oxidative dearomatization using FDMOs 
established, I sought to  apply these enzymes to the total synthesis of other tricyclic 
azaphilones through a one-pot dual-enzyme sequence. To provide access to these more 
densely functionalized natural product scaffolds, I investigate the AT PigD for it’s ability 
to mediate an acylation reaction of the dearomatized intermediate provide by AzaH. Once 
reaction conditions were optimized, I demonstrated PigD’s promiscuity towards several 
dearomatized orcinaldehyde analogs, in addition to showing its compatibility with the 
AzaH reaction conditions. With assistance from Dr. Ye Wang, these two enzymes were 
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applied in sequence on a preparative scale, in combination with a thioester ACP mimic, 
to give access to the natural product rubropunctatin and several analogs thereof. NMR 
studies of these compounds suggests the acylated intermediate undergoes a subsequent 
cyclization reaction with unexpected regioselectivity, granting access to the linear tricyclic 
azaphilone scaffold with unprecedented selectivity.  
 
5.2 Future Directions  
Having developed novel strategies to access azaphilone natural product analogs, 
we aim to continue exploring the substrate scope and improving the yield of the 
aforementioned one-pot dual-enzyme platform. This will include screening the 
transformation against other aromatic substrates containing broader structural diversity 
than those investigated in Chapter 4, in addition to investigating PigD’s ability to accept 
other acyl-donor reagents. In pursuit of greater atom economy, we seek to develop the 
use of truncated thioesters (such as N-acylcysteamine and thiophenol adducts) in place 
of the reported pantetheine-based thioester. We will also investigate acyl-donors with 
carbon chains of varying length and substitution to uncover the true substrate scope of 
PigD. 
To access tricyclic natural product analogs containing the opposite C7 
stereochemistry to those provided by AzaH, additional ATs will be identified through SSN 
analysis. We anticipate that investigation of enzymes related to PigD will uncover a 
protein capable of acylating dearomatized intermediates constructed by AfoD, ultimately 
providing increased control over the absolute configuration of the synthesized scaffolds. 
Once this route is established, it will be used to construct a large library of these tricyclic 
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azaphilones for SAR studies in collaboration with the Sexton Lab at the University of 
Michigan.  
Regarding the question surrounding the actual substrate for PigD and the 
mechanism for the observed annulation regioselectivity, synthetic standards of the 
proposed acylated/uncyclized intermediates are currently being synthesized by Dr. Ye 
Wang for further investigation. We anticipate that experiments with these substrates, in 
addition to others possessing different functional groups and properties, will help uncover 
whether the observed selectivity is mediated by PigD or if the selectivity is conferred by 
the dearomatized substrate itself.  
We envision that continued investigation of azaphilone compounds and the 
enzymes responsible for their construction will provide a means for additional 
development of these natural products towards potent pharmacophores. With newfound 
access to both enantioenriched azaphilone cores and the linear tricyclic azaphilone 
scaffold provided by the methods we’ve established, we aim to construct other related, 
highly decorated natural products and subsequent analogs using these techniques. We 
plan to modify our azaphilone tricycles through chemoenzymatic sequences to further 
diversify our growing library of compounds for biological investigation.  
Towards this goal, we speculate that other enzymes from the rubropunctatin 
biosynthetic pathway could be of particular interest, given their role in the biosynthesis of 
related natural products.21 For example: the oxidoreductases MrPigE and MrPigF, and 
the putative dehydrogenase MrPigH, are reported to manipulate the π system of the 
azaphilone core through reduction or oxidation of specific C–C bonds selectively, a feat 
that would be challenging with conventional chemical reagents.21 Given the observed 
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compatibility of the enzymes AzaH and PigD, we hypothesize that additional enzymes 
like these could be added to our current dual-enzyme system, allowing for the electronics 
of the azaphilone core to be tuned and for new analogs to be generated in one-pot. 
Examining and comparing tricyclic analogs with varying degrees of oxidation decorating 
the basic core in SAR studies could also help identify how these structural changes affect 
the biological activity of these molecules. This modular, biomimetic synthetic platform 
could provide streamlined access to novel chemical space in the form of new natural 
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